conclusion for breast cancer essay

Home — Essay Samples — Nursing & Health — Breast Cancer — Miracle in My Life: My Mother’s Battle with Breast Cancer

Miracle in My Life: My Mother's Battle with Breast Cancer

• Categories: Breast Cancer Self Reflection

About this sample

Words: 1172 |

Published: Aug 31, 2023

Words: 1172 | Pages: 3 | 6 min read

Table of contents

Facing the horror of brca, family history of breast cancer, miracle healing from brca.

Cite this Essay

Let us write you an essay from scratch

• 450+ experts on 30 subjects ready to help
• Custom essay delivered in as few as 3 hours

Get high-quality help

Verified writer

• Expert in: Nursing & Health Life

+ 120 experts online

By clicking “Check Writers’ Offers”, you agree to our terms of service and privacy policy . We’ll occasionally send you promo and account related email

No need to pay just yet!

Related Essays

2 pages / 779 words

3 pages / 1211 words

1 pages / 506 words

2 pages / 844 words

Remember! This is just a sample.

You can get your custom paper by one of our expert writers.

121 writers online

Still can’t find what you need?

Browse our vast selection of original essay samples, each expertly formatted and styled

Related Essays on Breast Cancer

Breast cancer is the most common cancer among women worldwide, with an estimated 2.3 million new cases diagnosed in 2020. Understanding the stages of breast cancer is crucial for early detection, treatment planning, and [...]

Brief overview of breast cancer awareness and its goals Role of breast cancer advocates in raising funds and lobbying for better care The cultural aspect of breast cancer advocacy and pink ribbon culture The [...]

Summary - Breast cancer is a highly common cancer in women, that develops in the breast tissue. This article discusses the treatment of breast cancer and the importance of a good cancer care team for prolong relief. There are [...]

Many women all over the world have been known to be victims of breast cancer. The seriousness of the disease is known to surpass many diseases known in the history of man. Various remedies have however been sought following [...]

Cancer research in UK found that there is a gene in skin cancers that grows rapidly and heals itself. Scientists say that the skin cancer is mostly caused by a fault in the gene called asTGFBR1. The disease of skin cancer is [...]

Bladder Cancer that is in an early stage of growth may not produce any noticeable signs or symptoms. The most common sign of BC is hematuria (bloody urine; urine that appears bright red or rusty) usually is painless and may [...]

Related Topics

By clicking “Send”, you agree to our Terms of service and Privacy statement . We will occasionally send you account related emails.

Where do you want us to send this sample?

By clicking “Continue”, you agree to our terms of service and privacy policy.

Be careful. This essay is not unique

This essay was donated by a student and is likely to have been used and submitted before

Download this Sample

Free samples may contain mistakes and not unique parts

Sorry, we could not paraphrase this essay. Our professional writers can rewrite it and get you a unique paper.

Please check your inbox.

We can write you a custom essay that will follow your exact instructions and meet the deadlines. Let's fix your grades together!

Get Your Personalized Essay in 3 Hours or Less!

We use cookies to personalyze your web-site experience. By continuing we’ll assume you board with our cookie policy .

• Instructions Followed To The Letter
• Deadlines Met At Every Stage
• Unique And Plagiarism Free

Understanding Breast Cancer

A foundational guide explaining the biology, types, stages, and risk factors of breast cancer, aiming to educate readers on its complexities and common misconceptions. At PapersOwl too, you can discover numerous free essay illustrations related to Breast Cancer topic.

How it works

This paper will clarify what Breast Cancer is. It will explain the symptoms, treatment options, and other useful information regarding this disease. The first thing to know about Breast Cancer is understanding what it is. According to the Cancer.org website, breast cancer begins when cells in the bosom begin to spread out of control. The tumor that is formed from these cells may be detected on an x-ray or can be felt as a lump. Malignancy can advance into neighboring tissues or trickle to distant places within the individual.

1 There are a few different ways to find out if someone has Breast Cancer. One of them is by a woman giving them self a breast self-exam. This is also one of the things Gynecologist check for at a woman’s annual exam. Gynecologists checks for lumps in all women at their annual Gynecology appointments. Of course, not all cancers can be found just by doing this exam, that’s why there are tests that can be done to find the Breast Cancer. However, it is an important precaution for women to take for themselves.

There are imaging tests to screen an area that is of concern. These tests are called mammograms. The other tests are breast Ultrasound, Breast MRI Scans, Molecular Breast Imaging, Optical Imaging Test, Electrical impedance imaging, and Elastography. There is a form of mammogram that is more recent. This exam is called Breast tomosynthesis, which is also known as 3D mammography. In this evaluation, a machine takes low-dose radioactive imagery as it maneuvers on the breast. The program then pieces images into a 3-dimensional print.1 If a test shows that a patient may have breast cancer, the patient will have to get a biopsy. There are a few distinct types of biopsies for checking cancer in the breast. A few require a needle, and others an incision.1 In 2018, there are various Breast Cancer Treatment options available for breast cancer patients. These treatment options are available to Breast Cancer patients who range from having early-stage cancer to advanced breast cancer.

When patients are at the point of deciding their treatments for their breast cancer, a clinical trial is often emboldened to think about as an option. 5 There is literature to suggest that it is always a good idea to get a second opinion when it comes to the plan for treatment of breast cancer. It’s so important to that a patient is sure they are comfortable with the plan of treatment for their cancer. As mentioned earlier, there are various breast cancer treatment options that are available. Surgery, Chemo Therapy, Radiation Therapy, Hormonal Therapy, Targeted Immunotherapy, and clinical trials. There are also medications that can be prescribed to the patient to treat cancer-and treatment-related pain.3 The therapy or treatment a breast cancer patient receives is dependent on what stage cancer they have, for example, if a person has a stage IV Breast Cancer, which is metastatic, they would be treated with a therapy called Systemic Therapy. This can also subsume Chemotherapy, hormone therapy, or a miscellany of these treatments that were just mentioned.2 There are a distinct number of things that society can do to lower the chance of getting breast cancer. Habit changing is one way, having a limit to alcohol consumption is helpful to lower the possibility. Information given online mentions not smoking, maintaining one’s healthy weight, breastfeeding, and averting from any radioactivity, or pollution from ecological surroundings.

From research, Breast Cancer is one of the top two most prevalent reasons for death in America. Cancer of the lungs is the number one cause of death. Unfortunately, in 2018, over forty thousand women are believed to pass away due breast cancer. A person’s probability of getting this cancer increases if she has a family member who has also been determined to have breast cancer.4 There are tests that determine if a person has a pattern of development for cancer that runs in their family. These tests focus on finding the unhealthy BRCA1 or BRCA2 mutation in their gene. The DNA of a person is what is required for testing the mutations of BRCA1 and BRCA2. Typically, from the sample of the subject’s sputum or their blood. The human genes BRCA1 and BRCA2 are genes which create proteins that are tumor suppressors. These said proteins aid in repairing impaired DNA. Consequently, important in securing the balance, or cohesion of all the cell’s hereditary make up. Explicit genetic alterations in BRCA2 and BRCA2 reputably boosts the possibility of cancer in the breast and ovaries of females. Individuals who have the mutations in BRCA1 and BRCA2 that have been passed down to them, are likely to get ovarian and breast cancers at ages earlier than those who are without the mutations of the above-mentioned BRCA1 and BRCA2.7 Early detection is the key, it’s imperative that women and men get their routine checkups to make sure they don’t have any of the abnormalities like lumps that can be found in the breasts. Paying attention and knowing your body is also important. If someone is experiencing different things or symptoms. It is critical that they get these symptoms looked and taken care of right away. It is always better to be cautious than to be sorry, later.

Cite this page

Understanding Breast Cancer. (2019, May 06). Retrieved from https://papersowl.com/examples/understanding-breast-cancer/

"Understanding Breast Cancer." PapersOwl.com , 6 May 2019, https://papersowl.com/examples/understanding-breast-cancer/

PapersOwl.com. (2019). Understanding Breast Cancer . [Online]. Available at: https://papersowl.com/examples/understanding-breast-cancer/ [Accessed: 24 May. 2024]

"Understanding Breast Cancer." PapersOwl.com, May 06, 2019. Accessed May 24, 2024. https://papersowl.com/examples/understanding-breast-cancer/

"Understanding Breast Cancer," PapersOwl.com , 06-May-2019. [Online]. Available: https://papersowl.com/examples/understanding-breast-cancer/. [Accessed: 24-May-2024]

PapersOwl.com. (2019). Understanding Breast Cancer . [Online]. Available at: https://papersowl.com/examples/understanding-breast-cancer/ [Accessed: 24-May-2024]

Don't let plagiarism ruin your grade

Hire a writer to get a unique paper crafted to your needs.

Our writers will help you fix any mistakes and get an A+!

Please check your inbox.

You can order an original essay written according to your instructions.

Trusted by over 1 million students worldwide

1. Tell Us Your Requirements

2. Pick your perfect writer

3. Get Your Paper and Pay

Hi! I'm Amy, your personal assistant!

Don't know where to start? Give me your paper requirements and I connect you to an academic expert.

short deadlines

100% Plagiarism-Free

Certified writers

• In-person and virtual events just for HCPs

• Conferences
• Publications
• Biomarker Consortium

Conclusion and Final Thoughts on Managing Breast Cancer

For High-Definition, Click

In the final segment, moderator, Adam M. Brufsky, MD, PhD, asks each panelist for their final thoughts on the management of metastatic breast cancer. Sara Hurvitz, MD, notes her excitement over the number of therapeutic options available to treat patients with HER2 and ER-positive breast cancer, particularly since many of these treatments have less toxicity.

The depth of understanding of tumor microenvironments and biology in breast cancer is due to a global collaboration among researchers, states Edith A. Perez, MD. Additionally, she believes, panel discussions, like this one, help to translate research into clinical practice.

Significant advances have been made in recent years in the treatment of patients with ER-positive disease, believes Hope S. Rugo, MD. Additionally, the therapies developed to treat metastatic disease are beginning to transition into the early-stage setting, representing a significant increase in the number of neoadjuvant treatments. Furthermore, Rugo adds, there is now a better understanding of the subtypes of ER-positive and overcoming resistance, which has improved outcomes for patients.

The level of competition in this space has resulted in the rapid development of novel treatments, says Joyce A. O'Shaughnessy, MD. Therapies have advanced from phase I trials quickly into phase III. In the end, this rapid development greatly benefits patients with this disease.

The treatment of breast cancer is at a tipping point, now that the biology of intrinsic subtypes has been revealed, states Andrew D. Seidman, MD. The level of molecular knowledge allows for the rational development of targeted therapeutics and combinations that avoid feedback looks that overcome therapeutic efficacy, Seidman states. Echoing this, Brufsky notes this is the beginning of the genomic era of our understanding of breast cancer, which may have implications for clinical trial design.

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Inavolisib Receives FDA Breakthrough Therapy Designation for PIK3CA-Mutated, HR+/HER2– Breast Cancer

Revisit the OncLive On Air Episodes From February 2024

Real-World Study Sheds Light on Treatment Sequences and Second-Line Outcomes in HER2+ Breast Cancer

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

Latest Conference Coverage

AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies

Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence

Addressing Research Into the Association Between Tumor Mutations and Responses in RCC

2 Commerce Drive Cranbury, NJ 08512

609-716-7777

We use cookies to enhance our website for you. Proceed if you agree to this policy or learn more about it.

• Essay Database >
• Essay Examples >
• Essays Topics >
• Essay on Nursing

Breast Cancer Essay Examples

Type of paper: Essay

Topic: Nursing , DNA , Breast Cancer , Treatment , Cancer , Gene , Genetics , Receptor

Words: 1000

Published: 07/05/2021

ORDER PAPER LIKE THIS

Introduction

Breast cancer is a genetic disorder so common that it has claimed the lives of many women all over the world with statistics showing that it’s concentrated on the age of 45 - 55 years. Breast cancer, along with the other category of this disease is the product of the occurrence of a metastasized tumor. Neoplasm forms when genes are expressed abnormally such that the natural outcome of somatic cells is associated. Mutation, deletion and amplification of genes that control cellular growth and differentiation also cause the formation of a neoplasm. Thus, it is very critical to understand the genetic components of tumors because this understanding can be the missing puzzle in finding molecular pathways of malignant tumors. Molecular pathways are essential because they may provide useful information to identify and treat molecular targets for immunotherapy. Several treatments have been developed for breast cancer in the past 40 years. From mastectomy, aggressive treatments were introduced to conserve the breast of the patient. These treatments include adjuvant chemotherapy and hormonal therapy.

The introduction of hormonal therapy during the 1980s has reduced the number of estrogen receptor and progesterone receptor positive cancer. The number of dying women who are suffering from this debilitating disease continues to dwindle as the monoclonal antibody trastuzumab was introduced in the 1990s to treat HER2 positive (human epidermal growth factor receptor) breast cancer. Trastuzumab is the first monoclonal antibody that was approved for immunotherapy that targets oncogenes and has proven to be beneficial for women who are diagnosed with HER2 positive breast cancer.

The HER2 human epidermal receptor is a part of the family of epithelial tyrosine kinase receptors (HER1, HER2, HER3 and HER4) that exists in different combinations. Tyrosine kinase receptors interact with a ligand, an ion that attaches to a metal atom that forms a complex, to facilitate signaling pathways for intercellular communication. Breast cancers that have great excess of HER2 protein are more destructive than other breast cancer. The prognosis and chance of survival is not optimistic as that of patients that does not have an excessive number of HER2 genes.

The precise binding of a ligand to a receptor allows the interaction of a heterodimer, a protein made up of two polypeptide sequence having conflicting composition in the progression, number, or type amino acid deposit, that is responsible in determining which signal pathway is stimulated to control cell growth (3). HER2’s pairing with a ligand in a non-specific sequence has allowed the survival and differentiation of cells. HER2 also promotes ligand binding with heterodimers. As a consequence, the rate of incorporating the ligand-heterodimer complex in intracellular signaling decreases as compared to other heterodimer complexes. Further, HER2 homodimer is inherently active. When the HER2 gene is amplified, HER2 protein increases nearly a hundred times leading to HER2 homodimerization and activation and dysregulation of receptor and this initiates the progression of the tumor in the body.

In a recent trastuzumab-based chemotherapy research, it was shown that the level of amplification of HER2 gene is a good predictor of the sensitivity of a patient to therapy and cancer survival rates. It could link the significance of advanced cancer genome sequencing playing a very crucial role in understanding the nature of HER2 as a potential gene target for cancer treatments.

Mutation in HER2 gene is comparable to the insertion of nine base pairs in exon 20 in the EGFR of HER2 domains. As was previously mentioned, HER2 selectively forms heterodimer complexes with EGF receptors. When mutation occurs, the ATP binding pockets of these receptors increases tyrosine kinase activity. Hence, signal peptides are excessively phosphorylated while neoplastic cells grow in number, its sensitivity or resistance to tyrosine kinase activity decreases. This indicates the need to investigate the insertion in exon 20 of HER2 gene because mutations in HER2 gene can be biomarker for immunotherapy.

SNP has greatly helped oncology with its genetic alterations like insertions and removals and signal transduction study which provided researches the important information into the source and consequence of many varying kinds of cancer, pointing to suitable detection and healing. It is therefore the aim of this study to determine the presence of mutation in the HER2 gene and examine how mutation affects the sensitivity of patients to drugs that target the receptor. This study was preformed by isolating the genomic DNA from human breast cancer cell line. Polymerase chain reaction (PCR) was used to amplify the exon 20 0f the HER2 gene. After purifying the PCR products, the isolated HER2 gene was ligated to pJet 1.2 vector. The pJet/HEX20 was transformed in E. coli.

The plasmids were isolated and analyzed by restriction digestion with HindIII restriction enzyme to verify the presence of the insert. Then it was intended that the DNA would be sequenced and observed for any mutations in the cloned gene.

- Incorvati J, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. Journal of Hematology and Oncology. 2013; 6(38):1-9. - Ayoub N, Lucas C, Kaddoumi A. Genomics and pharmacogenomics of breast cancer: current knowledge and trends. Asian Pacific Journal of Cancer Prevention. 2011; 12, 1127-1140. - Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Annals of Oncology. 2001; 12(1): S35-S41. - Zito C, Riches D, Kolmakova J, Simons J, Egholm M, Stern D. Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer. Genes, Chromosomes and Cancer. 2008; 47, 633-638. - Gomez C, Plaza J, Salud A, Pons F, Fonseca P. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. Journal of Clinical Oncology. 2013; 48, 9070. - Nicos M, Krawczyk P, Mlak R, Sawicki M, Jarosz B. The presence of HER2 Exon 20 insertion in patients with central nervous system metastases. Pneumonologia i Alergolia Polska. 2013; 81, 294-297.

Cite this page

Share with friends using:

Removal Request

Finished papers: 912

This paper is created by writer with

ID 256452206

If you want your paper to be:

Well-researched, fact-checked, and accurate

Original, fresh, based on current data

Eloquently written and immaculately formatted

275 words = 1 page double-spaced

Get your papers done by pros!

Other Pages

Example of research proposal on web site evaluation memo, example of report on discution of stategic management and evaluation of the body shop strategy, example of advanced financial management essay, essay on final exam civil war, example of hearing impairment and its impact on education research paper, example of essay on personal model of leadership, example of chinas presence in africa argumentative essay, my favorite place term paper examples, free critical thinking on marx vs freud, free book review on the life of mahatma gandhi, external debt sustainability of us essay sample, creative writing on mccarthys the road, hizballah the lebanese party of god and its rise to global terrorism research paper, example of research paper on discrimination or prejudice, research paper on healthy condition requires healthy lifestyle, transportation of energy research paper, example of course work on national oil, plum essays, trolley essays, kitten essays, absolutist essays, stupidity essays, machismo essays, patch essays, shaikh essays, mascia essays, fisk essays, assault case studies, apartment case studies, opera case studies, retention case studies, disneyland case studies, southwest airlines case studies, beach case studies, rhythm and blues research papers, inexperience research papers, malfunction research papers, landmark research papers, balance of power research papers, lattice research papers, naturalist research papers, international organization research papers.

Password recovery email has been sent to [email protected]

Use your new password to log in

You are not register!

By clicking Register, you agree to our Terms of Service and that you have read our Privacy Policy .

Now you can download documents directly to your device!

Check your email! An email with your password has already been sent to you! Now you can download documents directly to your device.

or Use the QR code to Save this Paper to Your Phone

The sample is NOT original!

Short on a deadline?

Don't waste time. Get help with 11% off using code - GETWOWED

No, thanks! I'm fine with missing my deadline

Breast Cancer Essays

Using whole genome sequencing for studying cancers.

Abstract Genome sequencing reveals the order of the bases that are present in the entire human genome. It is backed by automated deoxyribonucleic acid sequencing…

To Improve the Quality of Tomosynthesis Images

Background The increasing diagnosis of breast cancer in the US necessitates for a better clinically recognized modality for cancer detection to help in the reduction…

Research Designs

1. What is the relationship between alcohol and breast cancer? Appropriate research design This question can be best addressed through a correlational research design that…

Pathophysiological Development of Breast Cancer

Introduction Breast cancer is identified as one of the most prevalent type of cancer and the main cause of mortality associated with cancer in women…

Gloria Gemma Breast Cancer Resource Foundation Analysis

Gloria Gemma Breast Cancer Resource Foundation, a non-governmental organization, based in Rhode Island, was established in 2004 in the loving memory of Gloria Gemma who…

Breast Cancer Essay

Cancer is one of the diseases that have obligated the healthcare sector to focus on extensive research. The increasing mortality and morbidity rates associated with…

Primary Types of Cancer and How They Are Related

Introduction Cancer has remained a deadly disease for a long time, and the different types of cancer are related thus making it difficult to treat…

Genetics and breast cancer risk

Research Methodology Evidence Table Condition Study Design Author, Year No. of Subjects Statistically Significant Quality of Study Magnitude of Benefit Absolute Risk Reduction No. Needed…

Evidence-based plan for evaluating outcomes

This study will look at outcome evaluation in Evidence-Based Plan using the PICOT question: In women with family history of breast cancer (P), does education…

Humanities of breast cancer in women

Breast cancer among females has been the most common melanoma with the greatest fatal outcome rate as compared to other cancers that affect women. It…

Why you should not smoke cigarettes

Cigarette smoking is one of the riskiest behaviors that lead to serious health problems. While active smokers are the mainly affected, cigarette smoking also affects…

• ☠️ Assisted Suicide
• Affordable Care Act
• Breast Cancer
• Genetic Engineering

Breast Cancer: Setting Priorities for Effectiveness Research (1990)

Chapter: conclusion, conclusions.

The committee came to four fundamental conclusions. First, we believe that the HCFA data sets, as presently constituted, can best be utilized to describe, track, and compare broad patterns of care for breast cancer according to subgroups of providers, practitioners, and patients. We fully support those goals of the Effectiveness Initiative. We offered three patient management areas—mammography (especially as a screening modality), therapeutic options (various surgical options, with and without radiation, chemotherapy, or hormonal therapy), and follow-up of patients treated for primary breast cancer—in which we believe effectiveness analyses would bear fruit. We suggested some of the variables that might have an important role in examinations of patterns (and variations) in care.

Second, we are less certain that at the present time the data sets lend themselves fully to the assessment of the important outcomes of therapeutic alternatives, believing that those outcomes presently proposed or available (e.g., death, proxy measures of complications of hospitalization) are insufficient to the task. We have taken seriously, however, the expressed intent of the framers of the Effectiveness Initiative that appropriate efforts for acquiring needed outcome data—either for the standard data sets themselves or for special projects—could and would be mounted. For this reason, and because ultimately we believe effectiveness research will falter without an ability to monitor or analyze outcomes appropriately, we have given strong emphasis in this report to outcome measurement; we hope that our suggestions here will strengthen that aspects of this work.

Third, we also wish to emphasize the need for appropriate case mix and severity adjustment or staging in effectiveness analyses and the need for ambulatory care data. The points raised concerning outcome measurement, such as mounting appropriate strategies for acquiring such data, apply as well.

Fourth, in our deliberations, many clinical questions were raised that are clearly in the purview of biomedical and clinical research, such as those relating to the appropriate physiologic variables in a staging index or to decisions to biopsy a patient following a positive screening mammogram. We do not believe that the program should try to tackle questions (such as these) that are best handled by prospective clinical RCTs. There are areas, however, where RCTs within the effectiveness arena might be considered. Among these might be alternative systems for delivering certain types of care for breast cancer, good mechanisms of feedback of practice-variation information to physicians, and ways to make information available to patients. We did not discuss these in any detail, but we encourage the agencies sponsoring effectiveness research to take them under advisement.

READ FREE ONLINE

Welcome to OpenBook!

You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

Do you want to take a quick tour of the OpenBook's features?

Show this book's table of contents , where you can jump to any chapter by name.

...or use these buttons to go back to the previous chapter or skip to the next one.

Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

Switch between the Original Pages , where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

To search the entire text of this book, type in your search term here and press Enter .

Share a link to this book page on your preferred social network or via email.

View our suggested citation for this chapter.

Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

Get Email Updates

Do you enjoy reading reports from the Academies online for free ? Sign up for email notifications and we'll let you know about new publications in your areas of interest when they're released.

• Undergraduate
• High School
• Architecture
• American History
• Asian History
• Antique Literature
• American Literature
• Asian Literature
• Classic English Literature
• World Literature
• Creative Writing
• Linguistics
• Criminal Justice
• Legal Issues
• Anthropology
• Archaeology
• Political Science
• World Affairs
• African-American Studies
• East European Studies
• Latin-American Studies
• Native-American Studies
• West European Studies
• Family and Consumer Science
• Social Issues
• Women and Gender Studies
• Social Work
• Natural Sciences
• Pharmacology
• Earth science
• Agriculture
• Agricultural Studies
• Computer Science
• IT Management
• Mathematics
• Investments
• Engineering and Technology
• Engineering
• Aeronautics
• Medicine and Health
• Alternative Medicine
• Communications and Media
• Advertising
• Communication Strategies
• Public Relations
• Educational Theories
• Teacher's Career
• Chicago/Turabian
• Company Analysis
• Education Theories
• Shakespeare
• Canadian Studies
• Food Safety
• Relation of Global Warming and Extreme Weather Condition
• Movie Review
• Admission Essay
• Annotated Bibliography
• Application Essay
• Article Critique
• Article Review
• Article Writing
• Book Review
• Business Plan
• Business Proposal
• Capstone Project
• Cover Letter
• Creative Essay
• Dissertation
• Dissertation - Abstract
• Dissertation - Conclusion
• Dissertation - Discussion
• Dissertation - Hypothesis
• Dissertation - Introduction
• Dissertation - Literature
• Dissertation - Methodology
• Dissertation - Results
• GCSE Coursework
• Grant Proposal
• Marketing Plan
• Multiple Choice Quiz
• Personal Statement
• Power Point Presentation
• Power Point Presentation With Speaker Notes
• Questionnaire
• Reaction Paper

Research Paper

• Research Proposal
• SWOT analysis
• Thesis Paper
• Online Quiz
• Literature Review
• Movie Analysis
• Statistics problem
• Math Problem
• All papers examples
• How It Works
• Money Back Policy
• Terms of Use
• Privacy Policy
• We Are Hiring

What Is Breast Cancer? Essay Example

Pages: 5

Words: 1376

Hire a Writer for Custom Essay

Use 10% Off Discount: "custom10" in 1 Click 👇

You are free to use it as an inspiration or a source for your own work.

Suspicion for breast cancer is one of the most horrifying diagnoses any women can ever receive. Breast cancer brings forth numerous dreads, for instance fear of surgical treatment, loss of body image and attractiveness, or even death. There are however some quite effective ways of dealing with these fears. First of all, each woman should be well informed about the essence of the disease. Knowledge is a great tool when you are facing the health problem since it can help you to make the best decisions regarding own care. Secondly, professional consultation is necessary. Issues like this are best talked over with the personal doctor on an individual basis. Being knowledgeable about disease specifics any woman would be able to prevent it from uncontrollable development and avoid harmful consequences it may cause.

So what breast cancer actually is? It is a type of cancer that affects the breast; it typically starts in the inner lining of the milk ducts or lobules. Less frequently, breast cancer can starts in the stromal tissues that consist of the fatty and fibrous connective tissues of the breast. “Over time, cancer cells can invade nearby healthy breast tissue and make their way into the underarm lymph nodes, small organs that filter out foreign substances in the body. If cancer cells get into the lymph nodes, they then have a pathway into other parts of the body.” (Breastcancer.org, 2008) As a process it can be described as an unrestrained growth of breast cells. “Cancer occurs as a result of mutations, or abnormal changes, in the genes responsible for regulating the growth of cells and keeping them healthy.” (Breastcancer.org, 2008) A tumor that is formed as a result of such processes can be of two types: a benign one, and a malignant one. While benign tumors are causing no danger and are thus not considered cancerous (their cells are mostly normal in appearance, they grow gradually, and do not occupy nearby tissues or extend to other parts of the body), malignant tumors are cancerous (if being ignored, malignant cells will eventually spread outside the original tumor to other parts of the body). Figure 1 illustrates the structure of a breast, providing better understanding of how the processes of tumor development are performed.

C Dilated section of duct to hold milk

F Pectoralis major muscle

G Chest wall/rib cage

Enlargement

A Normal duct cells

B Basement membrane

C Lumen (center of duct)

Figure 1. Breast Anatomy (Profile).

Note . From Breastcancer.org. (2008). What is breast cancer? Retrieved November 14, 2099, from http://www.breastcancer.org/symptoms/understand_bc/what_is_bc.jsp

There are diverse types of breast cancer, with varying stages (spread), aggressiveness, and genetic makeup. It is important to know that the effectiveness of treatment mostly depends on the stage at which cancer was discovered. It implies that each woman should take care of own body and pay deliberate attention to the processes it performs. The following Figure 2 illustrates how stage of diagnosis and surviving the illness are related.

Figure 2. Cancer of the Female Breast. 5-Year SEER Conditional Relative Survival Rates and 95% Confidence Intervals

Note . From National Cancer Institute. Surveillance Epidemiology and End Results: Cancer Statistics Review 1975-2006 . Retrieved November 14, 2009, from http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section=4&page=sect_04_zfig.11.html#tableContent

The reason I have chosen to discuss the subject of breast cancer is that it is getting extremely spread worldwide. These days breast cancer is stated to be the second most common type of cancer after lung cancer. It is also the second most common cause of cancer death in women in the U.S. We live in a world invaded with pollutants, hormones, pesticides, smoking, alcohol use, obesity, stress etc., each of which can be an indirect cause of an abnormal cell growth. “Or maybe your cells just made a mistake one day when they were making new genes to pass on to their baby cells. Perhaps there was a misprint in the genetic instruction manual that said switch growth on instead of growth off. ” ((Breastcancer.org, 2008) The statistics of female breast incidence (1996-2006) are given in the following

Cancer of the Female Breast (Invasive). Age-adjusted SEER Incidence [1] Rates by Year, Race and Age

Note . From National Cancer Institute. Surveillance Epidemiology and End Results: Cancer Statistics Review 1975-2006 . Retrieved November 14, 2009, from http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section=4&page=sect_04_table.07.html

Exact causes of breast cancer are still unclear, and most doctors will never be able to explain why this or that woman develops breast cancer while another does not. There are however some risk factors that increase the possibility of developing a disease. These may be: age (the risk increases as a woman gets older), family history (having other relatives with breast cancer increases the risk), race (white women are affected more frequently), physical activity (lack of activity increases risk), body weight (the chance of getting breast cancer is higher in women who are overweight or obese), drinking alcohol (the more alcohol a woman consume the bigger is a chance of cancer development), etc.

Symptoms of the breast cancer are not always obvious; they are usually invisible to an eye of an average person. If you have any suspicion or have mentioned something unusual going on with your body, it would be wiser to go to see the doctor, – home diagnosing usually fails. If a woman has a symptom (skin irritation or dimpling, breast/nipple pain, redness, scaliness, etc.) or screening test result indicates an availability of a tumor, further research should be made before final diagnose is established. Physical exams must be taken, mammogram or other imaging procedure are also of great use. Women with breast cancer have many treatment alternatives. Most women go through more than one form of treatment, among which there can be surgery, radiation therapy, chemotherapy, hormone therapy, and biological therapy.

Researching the topic I realized how many resources there are nowadays available for people with breast cancer. There is a huge amount of information concerning the issue of the disease. The problem is extremely topical one, and attempts to get people well informed are truly remarkable. There is also a possibility of contacting specialists provided, which helps to diagnose own problems without actually visiting a doctor. It shouldn’t surely exclude the visit to medical establishments in case of suspicious symptoms being noticed, but it is a great opportunity to get yourself knowledgeable and ready for any outcome. It also helps to analyze own health condition critically, without putting one’s entire trust in just one specialist’s opinion.

Breastcancer.org. (2008). What is breast cancer? Retrieved November 14, 2099, from http://www.breastcancer.org/symptoms/understand_bc/what_is_bc.jsp

National Cancer Institute: Surveillance Epidemiology and End Results . Cancer Statistics Review 1975-2006 : Annual Incidence Rates. Retrieved November 14, 2009, from http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section=4&page=sect_04_table.07.html

National Cancer Institute: Surveillance Epidemiology and End Results . Cancer Statistics Review 1975-2006 : 5-Year SEER Conditional Relative Survival Rates .  Retrieved November 14, 2009, from http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section=4&page=sect_04_zfig.11.html#tableContent

[1] SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups – Census P25-1130).

Stuck with your Essay?

Get in touch with one of our experts for instant help!

Investigation of Electronic Music, Research Paper Example

Value Added Analysis, Essay Example

Time is precious

don’t waste it!

Plagiarism-free guarantee

Privacy guarantee

Secure checkout

Money back guarantee

Related Essay Samples & Examples

Voting as a civic responsibility, essay example.

Pages: 1

Words: 287

Utilitarianism and Its Applications, Essay Example

Words: 356

The Age-Related Changes of the Older Person, Essay Example

Pages: 2

Words: 448

The Problems ESOL Teachers Face, Essay Example

Pages: 8

Words: 2293

Should English Be the Primary Language? Essay Example

Pages: 4

Words: 999

The Term “Social Construction of Reality”, Essay Example

Words: 371

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• News & Views
• Published: 22 May 2024

Breast cancer

Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain

• Maria Vittoria Dieci   ORCID: orcid.org/0000-0002-3967-9861 1 , 2 &
• Valentina Guarneri 1 , 2  

Nature Reviews Clinical Oncology ( 2024 ) Cite this article

1 Altmetric

Metrics details

• Therapeutics

De-escalation of treatment for HER2 + breast cancer is a priority, given the increase in cure rates owing in part to improved HER2-targeted therapies. In this regard, the neoadjuvant approach provides the ideal platform to test less-intensive treatment regimens. Here we highlight a study that demonstrated the role of the metabolic response after dual HER2 blockade as a method of selecting patients who are most likely to benefit from chemotherapy-free neoadjuvant therapy.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

195,33 € per year

only 16,28 € per issue

Buy this article

• Purchase on Springer Link
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Pérez-García, J. M. et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet 403 , 1649–1659 (2024).

Article   PubMed   Google Scholar  

Miglietta, F., Dieci, M. V., Griguolo, G. & Guarneri, V. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. Cancer Treat. Rev. 98 , 102222 (2021).

Article   CAS   PubMed   Google Scholar  

Llombart-Cussac, A. et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 18 , 545–554 (2017).

Guarneri, V. et al. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Ann. Oncol. 30 , 921–926 (2019).

Article   CAS   PubMed   PubMed Central   Google Scholar  

Tolaney, S. M. et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 24 , 273–285 (2023).

Pérez-García, J. M. et al. Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 22 , 858–871 (2021).

van Mackelenbergh, M. T. et al. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J. Clin. Oncol. 41 , 2998–3008 (2023).

Squifflet, P. et al. Re-evaluation of pathologic complete response as a surrogate for event-free and overall survival in human epidermal growth factor receptor 2-positive, early breast cancer treated with neoadjuvant therapy including anti-human epidermal growth factor receptor 2 therapy. J. Clin. Oncol. 41 , 2988–2997 (2023).

Dieci, M. V. et al. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. NPJ Breast Cancer 9 , 6 (2023).

Prat, A. et al. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. J. Natl. Cancer Inst. 112 , 46–54 (2020).

Download references

Author information

Authors and affiliations.

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy

Maria Vittoria Dieci & Valentina Guarneri

Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy

You can also search for this author in PubMed   Google Scholar

Corresponding author

Correspondence to Valentina Guarneri .

Ethics declarations

Competing interests.

M.V.D. has acted as a consultant and/or advisor of AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, MSD, Novartis, Pfizer, Roche and Seagen. V.G. has acted as a consultant and/or advisor board membership for AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Menarini Stemline, Merck Serono, MSD, Novartis, Olema Oncology, Pfizer, and Pierre Fabre, has acted as a speaker for AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, GSK, Menarini Stemline, Novartis, Roche and Zentiva and has received personal fees for expert testimony from Eli Lilly.

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Dieci, M.V., Guarneri, V. Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain. Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00907-w

Download citation

Published : 22 May 2024

DOI : https://doi.org/10.1038/s41571-024-00907-w

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Best Practices in Breast Cancer Care Essay

Current practices in supporting women with breast cancer.

Treatment guidelines for women with breast cancer include not only diagnostics and therapy but also practices aimed at maintaining patients after diagnosis and treatment. Tompkins et al. (2016) suggest that increasing the number of breast cancer survivors requires monitoring their condition and supporting them through the essential care approaches as a continuation of the clinical practice. Based on this, the final stage of therapy should include comprehensive support for patients with breast cancer as one of the main health care practices within the framework of current treatment guidelines. Therefore, current models of the latter stage of treatment should involve a written plan of care, as well as support from health workers and breast cancer nurses (BCNs) (Tompkins et al., 2016).

However, it is necessary to bear in mind that many patients after therapy do not receive sufficient personalized support. The reason for this is the fact that current guidelines require self-management of women, which may be ineffective in cases of overburdened women (Tompkins et al., 2016). This indicates gaps in supporting practices of women after diagnosis or survivors.

Thereupon, current research insists on the use of methods to support women after breast cancer treatment, along with other practitioners, and points to the importance of a personalized approach in addition to self-control. It is evident that external help and counseling should be a part of the clinical practice of caring for women with breast cancer. Tompkins et al. (2016) emphasize that self-control is not sufficient in many cases of patient care, which indicates the importance of using new models of external evaluation and assistance.

Other researchers, for example, Kirshbaum et al. (2016), also insist on the need for further patient care. For example, planned care, which comprises women’s reassurance and support, admits one to monitor the condition of patients and the possibility of relapses, as well as offering emotional assistance (Kirshbaum et al., 2016). Therefore, the analysis of research allows one to conclude that self-service cannot be the basis of care and subsequent professional approach is relevant for the best practices.

Women’s Health Initiative Study on the Controversial Status of External Support for Patients with Breast Cancer

Supportive care for women diagnosed with breast cancer, as well as its results, occupy an important place in the study conducted by the Women’s Health Initiative (WHI). The study examines the relationship between social support and overall health and mortality among women with breast cancer based on a cohort selected by WHI (Kroenke et al., 2012). Accordingly, an assessment of the relationship between external care and professional clinical care and the ability of patients to cope with the disease and treatment provide the identification of best practices.

Kroenke et al. (2012) discuss the significant impact of supporting close relatives as a method of physical and emotional care, emphasizing that wide social networks aggravate women’s health and increase mortality. These outcomes underscore the importance of external care, support and care as part of general clinical practice for breast cancer patients. However, the WHI study focuses on the need for family support and the avoidance of extensive social network involvement (Kroenke et al., 2012). This guidance indicates the negative influence of mass non-professional care and emphasizes the importance of professional help as the best practice in supporting cancer patients.

Differences in the Best Practices of Care for Women with Breast Cancer Diagnosis

The discussed studies examining current approaches to the follow-up care of women with breast cancer diagnosis or survivors focus on two sides of such guidelines. Hence, the WHI study confirms that women need support outside of therapy; however, the excessive social burden is detrimental to the health of patients (Kroenke et al., 2012). In this regard, it can be noted that the study by Tompkins et al. (2016) takes into account the lack of social support and self-control and proceeds further by offering various practices for the subsequent care of women under the guidance of health care professionals and breast care nurses.

I believe that, given the insufficient outcome of self-management and non-professional support, the most relevant practices are the implementation of standardized and extensive assistance from medical staff as the guiding principle of follow-up treatment. The article by Kirshbaum et al. (2016) confirms this by highlighting professional counseling and comprehensive testing and psychological support from the nurses as a significant part of the practice of treating women at an early stage of breast cancer or patients after therapy. Such an approach seems to be the most acceptable regarding the importance of expanding clinical practices beyond the limits of clinical treatment.

The implementation of planned practices to assess the status of women after breast cancer treatment and to maintain their physical and emotional state may improve outcomes and neutralize the problems of self-care. Therefore, such practices can promote monthly checks, provide strong emotional support as an essential stage of treatment, as well as a conviction that patients understand the treatment and care plan (Tharpe, Farley, & Jordan, 2016).

Even though follow-up assistance is not essential in mainstream clinical practice for breast cancer, studies prove this one of the fundamental needs. Patient counseling at each stage of treatment cannot be excluded from general guidelines.

Given that many women suffer from a lack of contact with a breast cancer nurse, professional follow-up care should be mandatory (Tompkins et al., 2016). The difference in the best approaches reflects the fact that the lack of professional follow-up care has a negative impact on the outcome of the treatment of women, while professional help represents the most successful practice. Thus, the analysis of research suggests that current clinical practice in patients with breast cancer cannot overlook the subsequent assessment and support that can achieve the best results for women.

Kirshbaum, M. N., Dent, J., Stephenson, J., Topping, A. E., Allinson, V., McCoy, M., & Brayford, S. (2016). Open access follow-up care for early breast cancer: A randomised controlled quality of life analysis . European Journal of Cancer Care , 26 (4). Web.

Kroenke, C. H., Michael, Y., Tindle, H., Gage, E., Chlebowski, R., Garcia, L., Messina, C., Manson, J. E., … Caan, B. J. (2012). Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis . Breast cancer research and treatment , 133 (1), 375-85. Web.

Tharpe, N. L., Farley, C., & Jordan, R. G. (2016). Clinical practice guidelines for midwifery & women’s health (5th ed.). Burlington, MA: Jones & Bartlett Publishers.

Tompkins, C., Scanlon, K., Scott, E., Ream, E., Harding, S., & Armes, J. (2016). Survivorship care and support following treatment for breast cancer: A multi-ethnic comparative qualitative study of women’s experiences . BMC Health Services Research , 16 (1). Web.

• Breast Cancer Symptoms and Causes
• Breast Cancer: Treatment and Rehabilitation Options
• Breast Self-Exams Curbing Breast Cancer Mortality
• Understanding Pathophysiology of Cancers
• Registered Nurses and Cancer Patients
• Integumentary Disorders Diagnostics
• Malignant Melanoma: Pathology and Epidemiology
• Keytruda as an Innovative Cancer Control Tool
• Chicago (A-D)
• Chicago (N-B)

IvyPanda. (2021, July 9). Best Practices in Breast Cancer Care. https://ivypanda.com/essays/best-practices-in-breast-cancer-care/

"Best Practices in Breast Cancer Care." IvyPanda , 9 July 2021, ivypanda.com/essays/best-practices-in-breast-cancer-care/.

IvyPanda . (2021) 'Best Practices in Breast Cancer Care'. 9 July.

IvyPanda . 2021. "Best Practices in Breast Cancer Care." July 9, 2021. https://ivypanda.com/essays/best-practices-in-breast-cancer-care/.

1. IvyPanda . "Best Practices in Breast Cancer Care." July 9, 2021. https://ivypanda.com/essays/best-practices-in-breast-cancer-care/.

Bibliography

IvyPanda . "Best Practices in Breast Cancer Care." July 9, 2021. https://ivypanda.com/essays/best-practices-in-breast-cancer-care/.

Physical activity, metabolites, and breast cancer associations

• Find this author on Google Scholar
• Find this author on PubMed
• Search for this author on this site
• ORCID record for Eleanor L. Watts
• For correspondence: [email protected]
• Info/History
• Supplementary material
• Preview PDF

Background The effects of habitual physical activity on physiology and disease prevention are not fully understood. We examined the associations between physical activity, metabolites in systemic circulation, and breast cancer risk.

Methods Total physical activity levels were assessed using doubly labeled water, accelerometers, and previous day recalls in the IDATA study (N=707 participants, ages 50-74 years, 51% women). Assessments occurred 1-6 times over a 12-month period and blood samples were collected twice. Partial Spearman correlations were used to estimate associations between physical activity and 843 serum metabolites, corrected for multiple testing using the false discovery rate (p-adj<0.05). Associations between physical activity-associated metabolites and breast cancer were explored in a prospective cohort (621 cases, 621 controls) using conditional logistic regression.

Results Physical activity was associated with 164 metabolites, spanning a wide range of pathways, including many amino acid pathways, glucose homeostasis, and bile acid metabolism. Nine physical activity-associated metabolites were also associated with postmenopausal breast cancer risk. Key metabolites were N-acetylthreonine, isovalerylglycine, 2-methylbutyroylcarnitine (amino acids and derivatives), androsteroid monosulfate C19H28O6S (1), and X-21310. These metabolites were consistent with a protective role of physical activity on breast cancer prevention and particularly implicated a role for branched chain amino acid catabolism. Sphingomyelin (d18:1/20:1, d18:2/20:0) levels were lower in participants with higher physical activity energy expenditure and were also associated with lower breast cancer risk.

Conclusion Physical activity is associated with a broad range of metabolites, some of which are also associated with reduced breast cancer risk, highlighting potential metabolic pathways for cancer prevention.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was supported by the Intramural Research Program of the NIH at the National Cancer Institute and National Institute on Aging (USA). The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Special Studies Institutional Review Board of the National Cancer Institute, NIH gave ethical approval for this work and all participants signed informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Data Availability Statement

All bona fide researchers can apply to use the IDATA and PLCO resources for health-related research ( https://cdas.cancer.gov/ ).

View the discussion thread.

Supplementary Material

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Citation Manager Formats

• EndNote (tagged)
• EndNote 8 (xml)
• RefWorks Tagged
• Ref Manager
• Tweet Widget
• Facebook Like
• Google Plus One

Subject Area

• Epidemiology
• Addiction Medicine (324)
• Allergy and Immunology (632)
• Anesthesia (168)
• Cardiovascular Medicine (2397)
• Dentistry and Oral Medicine (289)
• Dermatology (207)
• Emergency Medicine (381)
• Endocrinology (including Diabetes Mellitus and Metabolic Disease) (846)
• Epidemiology (11789)
• Forensic Medicine (10)
• Gastroenterology (705)
• Genetic and Genomic Medicine (3763)
• Geriatric Medicine (350)
• Health Economics (637)
• Health Informatics (2406)
• Health Policy (937)
• Health Systems and Quality Improvement (904)
• Hematology (342)
• HIV/AIDS (785)
• Infectious Diseases (except HIV/AIDS) (13338)
• Intensive Care and Critical Care Medicine (769)
• Medical Education (367)
• Medical Ethics (105)
• Nephrology (401)
• Neurology (3521)
• Nursing (199)
• Nutrition (528)
• Obstetrics and Gynecology (677)
• Occupational and Environmental Health (667)
• Oncology (1830)
• Ophthalmology (538)
• Orthopedics (220)
• Otolaryngology (287)
• Pain Medicine (234)
• Palliative Medicine (66)
• Pathology (447)
• Pediatrics (1036)
• Pharmacology and Therapeutics (426)
• Primary Care Research (424)
• Psychiatry and Clinical Psychology (3186)
• Public and Global Health (6175)
• Radiology and Imaging (1288)
• Rehabilitation Medicine and Physical Therapy (751)
• Respiratory Medicine (831)
• Rheumatology (380)
• Sexual and Reproductive Health (372)
• Sports Medicine (324)
• Surgery (403)
• Toxicology (50)
• Transplantation (172)
• Urology (147)

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Cancer Control
• v.28; Jan-Dec 2021

Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective

Patricia piña-sánchez.

1 Oncology Research Unit, Oncology Hospital, Mexican Institute of Social Security, Mexico

Antonieta Chávez-González

Martha ruiz-tachiquín, eduardo vadillo, alberto monroy-garcía, juan josé montesinos, rocío grajales.

2 Department of Medical Oncology, Oncology Hospital, Mexican Institute of Social Security, Mexico

Marcos Gutiérrez de la Barrera

3 Clinical Research Division, Oncology Hospital, Mexican Institute of Social Security, Mexico

Hector Mayani

Since the second half of the 20th century, our knowledge about the biology of cancer has made extraordinary progress. Today, we understand cancer at the genomic and epigenomic levels, and we have identified the cell that starts neoplastic transformation and characterized the mechanisms for the invasion of other tissues. This knowledge has allowed novel drugs to be designed that act on specific molecular targets, the immune system to be trained and manipulated to increase its efficiency, and ever more effective therapeutic strategies to be developed. Nevertheless, we are still far from winning the war against cancer, and thus biomedical research in oncology must continue to be a global priority. Likewise, there is a need to reduce unequal access to medical services and improve prevention programs, especially in countries with a low human development index.

Introduction

During the last one hundred years, our understanding of the biology of cancer increased in an extraordinary way. 1 - 4 Such a progress has been particularly prompted during the last few decades because of technological and conceptual progress in a variety of fields, including massive next-generation sequencing, inclusion of “omic” sciences, high-resolution microscopy, molecular immunology, flow cytometry, analysis and sequencing of individual cells, new cell culture techniques, and the development of animal models, among others. Nevertheless, there are many questions yet to be answered and many problems to be solved regarding this disease. As a consequence, oncological research must be considered imperative.

Currently, cancer is one of the illnesses that causes more deaths worldwide. 5 According to data reported in 2020 by the World Health Organization (WHO), cancer is the second cause of death throughout the world, with 10 million deaths. 6 Clearly, cancer is still a leading problem worldwide. With this in mind, the objective of this article is to present a multidisciplinary and comprehensive overview of the disease. We will begin by analyzing cancer as a process, focusing on the current state of our knowledge on 4 specific aspects of its biology. Then, we will look at cancer as a global health problem, considering some epidemiological aspects, and discussing treatment, with a special focus on novel therapies. Finally, we present our vision on some of the challenges and perspectives of cancer in the 21 st century.

The Biology of Cancer

Cancer is a disease that begins with genetic and epigenetic alterations occurring in specific cells, some of which can spread and migrate to other tissues. 4 Although the biological processes affected in carcinogenesis and the evolution of neoplasms are many and widely different, we will focus on 4 aspects that are particularly relevant in tumor biology: genomic and epigenomic alterations that lead to cell transformation, the cells where these changes occur, and the processes of invasion and metastasis that, to an important degree, determine tumor aggressiveness.

Cancer Genomics

The genomics of cancer can be defined as the study of the complete sequence of DNA and its expression in tumor cells. Evidently, this study only becomes meaningful when compared to normal cells. The sequencing of the human genome, completed in 2003, was not only groundbreaking with respect to the knowledge of our gene pool, but also changed the way we study cancer. In the post-genomic era, various worldwide endeavors, such as the Human Cancer Genome Project , the Cancer Genome ATLAS (TCGA), the International Cancer Genome Consortium, and the Pan-Cancer Analysis Working Group (PCAWG), have contributed to the characterization of thousands of primary tumors from different neoplasias, generating more than 2.5 petabytes (10 15 ) of genomic, epigenomic, and proteomic information. This has led to the building of databases and analytical tools that are available for the study of cancer from an “omic” perspective, 7 , 8 and it has helped to modify classification and treatment of various neoplasms.

Studies in the past decade, including the work by the PCAWG, have shown that cancer generally begins with a small number of driving mutations (4 or 5 mutations) in particular genes, including oncogenes and tumor-suppressor genes. Mutations in TP53, a tumor-suppressor gene, for example, are found in more than half of all cancer types as an early event, and they are a hallmark of precancerous lesions. 9 - 12 From that point on, the evolution of tumors may take decades, throughout which the mutational spectrum of tumor cells changes significantly. Mutational analysis of more than 19 000 exomes revealed a collection of genomic signatures, some associated with defects in the mechanism of DNA repair. These studies also revealed the importance of alterations in non-coding regions of DNA. Thus, for example, it has been observed that various pathways of cell proliferation and chromatin remodeling are altered by mutations in coding regions, while pathways, such as WNT and NOTCH, can be disrupted by coding and non-coding mutations. To the present date, 19 955 genes that codify for proteins and 25 511 genes for non-coding RNAs have been identified ( https://www.gencodegenes.org/human/stats.html ). Based on this genomic catalogue, the COSMIC (Catalogue Of Somatic Mutations In Cancer) repository, the most robust database to date, has registered 37 288 077 coding mutations, 19 396 fusions, 1 207 190 copy number variants, and 15 642 672 non-coding variants reported up to August 2020 (v92) ( https://cosmic-blog.sanger.ac.uk/cosmic-release-v92/ ).

The genomic approach has accelerated the development of new cancer drugs. Indeed, two of the most relevant initiatives in recent years are ATOM (Accelerating Therapeutics for Opportunities in Medicine), which groups industry, government and academia, with the objective of accelerating the identification of drugs, 13 and the Connectivity Map (CMAP), a collection of transcriptional data obtained from cell lines treated with drugs for the discovery of functional connections between genes, diseases, and drugs. The CMAP 1.0 covered 1300 small molecules and more than 6000 signatures; meanwhile, the CMAP 2.0 with L1000 assay profiled more than 1.3 million samples and approximately 400 000 signatures. 14

The genomic study of tumors has had 2 fundamental contributions. On the one hand, it has allowed the confirmation and expansion of the concept of intratumor heterogeneity 15 , 16 ; and on the other, it has given rise to new classification systems for cancer. Based on the molecular classification developed by expression profiles, together with mutational and epigenomic profiles, a variety of molecular signatures have been identified, leading to the production of various commercial multigene panels. In breast cancer, for example, different panels have been developed, such as Pam50/Prosigna , Blue Print , OncotypeDX , MammaPrint , Prosigna , Endopredict , Breast Cancer Index , Mammostrat, and IHC4 . 17

Currently, the genomic/molecular study of cancer is more closely integrated with clinical practice, from the classification of neoplasms, as in tumors of the nervous system, 18 to its use in prediction, as in breast cancer. 17 Improvement in molecular methods and techniques has allowed the use of smaller amounts of biological material, as well as paraffin-embedded samples for genomic studies, both of which provide a wealth of information. 19 In addition, non-invasive methods, such as liquid biopsies, represent a great opportunity not only for the diagnosis of cancer, but also for follow-up, especially for unresectable tumors. 20

Research for the production of genomic information on cancer is presently dominated by several consortia, which has allowed the generation of a great quantity of data. However, most of these consortia and studies are performed in countries with a high human development index (HDI), and countries with a low HDI are not well represented in these large genomic studies. This is why initiatives such as Human Heredity and Health in Africa (H3Africa) for genomic research in Africa are essential. 21 Generation of new information and technological developments, such as third-generation sequencing, will undoubtedly continue to move forward in a multidisciplinary and complex systems context. However, the existing disparities in access to genomic tools for diagnosis, prognosis, and treatment of cancer will continue to be a pressing challenge at regional and social levels.

Cancer Epigenetics

Epigenetics studies the molecular mechanisms that produce hereditable changes in gene expression, without causing alterations in the DNA sequence. Epigenetic events are of 3 types: methylation of DNA and RNA, histone modification (acetylation, methylation, and phosphorylation), and the expression of non-coding RNA. Epigenetic aberrations can drive carcinogenesis when they alter chromosome conformation and the access to transcriptional machinery and to various regulatory elements (promoters, enhancers, and anchors for interaction with chromatin, for example). These changes may activate oncogenesis and silence tumor-suppressor mechanisms when they modulate coding and non-coding sequences (such as micro-RNAs and long-RNAs). This can then lead to uncontrolled growth, as well as the invasion and metastasis of cancer cells.

While genetic mutations are stable and irreversible, epigenetic alterations are dynamic and reversible; that is, there are several epigenomes, determined by space and time, which cause heterogeneity of the “epigenetic status” of tumors during their development and make them susceptible to environmental stimuli or chemotherapeutic treatment. 22 Epigenomic variability creates differences between cells, and this creates the need to analyze cells at the individual level. In the past, epigenetic analyses measured “average states” of cell populations. These studies revealed general mechanisms, such as the role of epigenetic marks on active or repressed transcriptional states, and established maps of epigenetic composition in a variety of cell types in normal and cancerous tissue. However, these approaches are difficult to use to examine events occurring in heterogeneous cell populations or in uncommon cell types. This has led to the development of new techniques that permit marking of a sequence on the epigenome and improvement in the recovery yield of epigenetic material from individual cells. This has helped to determine changes in DNA, RNA, and histones, chromatin accessibility, and chromosome conformation in a variety of neoplasms. 23 , 24

In cancer, DNA hypomethylation occurs on a global scale, while hypermethylation occurs in specific genomic loci, associated with abnormal nucleosome positioning and chromatin modifications. This information has allowed epigenomic profiles to be established in different types of neoplasms. In turn, these profiles have served as the basis to identify new neoplasm subgroups. For example, in triple negative breast cancer (TNBC), 25 and in hepatocellular carcinoma, 26 DNA methylation profiles have helped to the identification of distinct subgroups with clinical relevance. Epigenetic approaches have also helped to the development of prognostic tests to assess the sensitivity of cancer cells to specific drugs. 27

Epigenetic traits could be used to characterize intratumoral heterogeneity and determine the relevance of such a heterogeneity in clonal evolution and sensitivity to drugs. However, it is clear that heterogeneity is not only determined by genetic and epigenetic diversity resulting from clonal evolution of tumor cells, but also by the various cell populations that form the tumor microenvironment (TME). 28 Consequently, the epigenome of cancer cells is continually remodeled throughout tumorigenesis, during resistance to the activity of drugs, and in metastasis. 29 This makes therapeutic action based on epigenomic profiles difficult, although significant advances in this area have been reported. 30

During carcinogenesis and tumor progression, epigenetic modifications are categorized by their mechanisms of regulation ( Figure 1A ) and the various levels of structural complexity ( Figure 1B ). In addition, the epigenome can be modified by environmental stimuli, stochastic events, and genetic variations that impact the phenotype ( Figure 1C ). 31 , 32 The molecules that take part in these mechanisms/events/variations are therapeutic targets of interest with potential impact on clinical practice. There are studies on a wide variety of epidrugs, either alone or in combination, which improve antitumor efficacy. 33 However, the problems with these drugs must not be underestimated. For a considerable number of epigenetic compounds still being under study, the main challenge is to translate in vitro efficacy of nanomolar (nM) concentrations into well-tolerated and efficient clinical use. 34 The mechanisms of action of epidrugs may not be sufficiently controlled and could lead to diversion of the therapeutic target. 35 It is known that certain epidrugs, such as valproic acid, produce unwanted epigenetic changes 36 ; thus the need for a well-established safety profile before these drugs can be used in clinical therapy. Finally, resistance to certain epidrugs is another relevant problem. 37 , 38

Epigenetics of cancer. (A) Molecular mechanisms. (B) Structural hierarchy of epigenomics. (C) Factors affecting the epigenome. Modified from Refs. 31 and 32 .

As we learn about the epigenome of specific cell populations in cancer patients, a door opens to the evaluation of sensitivity tests and the search for new molecular markers for detection, prognosis, follow-up, and/or response to treatment at various levels of molecular regulation. Likewise, the horizon expands for therapeutic alternatives in oncology with the use of epidrugs, such as pharmacoepigenomic modulators for genes and key pathways, including methylation of promoters and regulation of micro-RNAs involved in chemoresponse and immune response in cancer. 39 There is no doubt that integrated approaches identifying stable pharmagenomic and epigenomic patterns and their relation with expression profiles and genetic functions will be more and more valuable in our fight against cancer.

Cancer Stem Cells

Tumors consist of different populations of neoplastic cells and a variety of elements that form part of the TME, including stromal cells and molecules of the extracellular matrix. 40 Such intratumoral heterogeneity becomes even more complex during clonal variation of transformed cells, as well as influence the elements of the TME have on these cells throughout specific times and places. 41 To explain the origin of cancer cell heterogeneity, 2 models have been put forward. The first proposes that mutations occur at random during development of the tumor in individual neoplastic cells, and this promotes the production of various tumor populations, which acquire specific growth and survival traits that lead them to evolve according to intratumor mechanisms of natural selection. 42 The second model proposes that each tumor begins as a single cell that possess 2 functional properties: it can self-renew and it can produce several types of terminal cells. As these 2 properties are characteristics of somatic stem cells, 43 the cells have been called cancer stem cells (CSCs). 44 According to this model, tumors must have a hierarchical organization, where self-renewing stem cells produce highly proliferating progenitor cells, unable to self-renew but with a high proliferation potential. The latter, in turn, give rise to terminal cells. 45 Current evidence indicates that both models may coexist in tumor progression. In agreement with this idea, new subclones could be produced as a result of a lack of genetic stability and mutational changes, in addition to the heterogeneity derived from the initial CSC and its descendants. Thus, in each tumor, a set of neoplastic cells with different genetic and epigenetic traits may be found, which would provide different phenotypic properties. 46

The CSC concept was originally presented in a model of acute myeloid leukemia. 47 The presence of CSCs was later proved in chronic myeloid leukemia, breast cancer, tumors of the central nervous system, lung cancer, colon cancer, liver cancer, prostate cancer, pancreatic cancer, melanoma, and cancer of the head and neck, amongst others. In all of these cases, detection of CSCs was based on separation of several cell populations according to expression of specific surface markers, such as CD133, CD44, CD24, CD117, and CD15. 48 It is noteworthy that in some solid tumors, and even in some hematopoietic ones, a combination of specific markers that allow the isolation of CSCs has not been found. Interestingly, in such tumors, a high percentage of cells with the capacity to start secondary tumors has been observed; thus, the terms Tumor Initiating Cells (TIC) or Leukemia Initiating Cells (LIC) have been adopted. 46

A relevant aspect of the biology of CSCs is that, just like normal stem cells, they can self-renew. Such self-renewal guarantees the maintenance or expansion of the tumor stem cell population. Another trait CSCs share with normal stem cells is their quiescence, first described in chronic myeloid leukemia. 49 The persistence of quiescent CSCs in solid tumors has been recently described in colorectal cancer, where quiescent clones can become dominant after therapy with oxaliplatin. 50 In non-hierarchical tumors, such as melanoma, the existence of slow-cycling cells that are resistant to antimitogenic agents has also been proved. 51 Such experimental evidence supports the idea that quiescent CSCs or TICs are responsible for both tumor resistance to antineoplastic drugs and clinical relapse after initial therapeutic success.

In addition to quiescence, CSCs use other mechanisms to resist the action of chemotherapeutic drugs. One of these is their increased numbers: upon diagnosis, a high number of CSCs are observed in most analyzed tumors, making treatment unable to destroy all of them. On the other hand, CSCs have a high number of molecular pumps that expulse drugs, as well as high numbers of antiapoptotic molecules. In addition, they have very efficient mechanisms to repair DNA damage. In general, these cells show changes in a variety of signaling pathways involved in proliferation, survival, differentiation, and self-renewal. It is worth highlighting that in recent years, many of these pathways have become potential therapeutic targets in the elimination of CSCs. 52 Another aspect that is highly relevant in understanding the biological behavior of CSCs is that they require a specific site for their development within the tissue where they are found that can provide whatever is needed for their survival and growth. These sites, known as niches, are made of various cells, both tumor and non-tumor, as well as a variety of non-cellular elements (extracellular matrix [ECM], soluble cytokines, ion concentration gradients, etc.), capable of regulating the physiology of CSCs in order to promote their expansion, the invasion of adjacent tissues, and metastasis. 53

It is important to consider that although a large number of surface markers have been identified that allow us to enrich and prospectively follow tumor stem cell populations, to this day there is no combination of markers that allows us to find these populations in all tumors, and it is yet unclear if all tumors present them. In this regard, it is necessary to develop new purification strategies based on the gene expression profiles of these cells, so that tumor heterogeneity is taken into account, as it is evident that a tumor can include multiple clones of CSCs that, in spite of being functional, are genetically different, and that these clones can vary throughout space (occupying different microenvironments and niches) and time (during the progression of a range of tumor stages). Such strategies, in addition to new in vitro and in vivo assays, will allow the development of new and improved CSC elimination strategies. This will certainly have an impact on the development of more efficient therapeutic alternatives.

Invasion and Metastasis

Nearly 90% of the mortality associated with cancer is related to metastasis. 54 This consists of a cascade of events ( Figure 2 ) that begins with the local invasion of a tumor into surrounding tissues, followed by intravasation of tumor cells into the blood stream or lymphatic circulation. Extravasation of neoplastic cells in areas distant from the primary tumor then leads to the formation of one or more micrometastatic lesions which subsequently proliferate to form clinically detectable lesions. 4 The cells that are able to produce metastasis must acquire migratory characteristics, which occur by a process known as epithelial–mesenchymal transition (EMT), that is, the partial loss of epithelial characteristics and the acquirement of mesenchymal traits. 55

Invasion and metastasis cascade. Invasion and metastasis can occur early or late during tumor progression. In either case, invasion to adjacent tissues is driven by stem-like cells (cancer stem cells) that acquire the epithelial–mesenchymal transition (EMT) (1). Once they reach sites adjacent to blood vessels, tumor cells (individually or in clusters) enter the blood (2). Tumor cells in circulation can adhere to endothelium and extravasation takes place (3). Other mechanisms alternative to extravasation can exist, such as angiopelosis, in which clusters of tumor cells are internalized by the endothelium. Furthermore, at certain sites, tumor cells can obstruct microvasculature and initiate a metastatic lesion right there. Sometimes, a tumor cells that has just exit circulation goes into an MET in order to become quiescent (4). Inflammatory signals can activate quiescent metastatic cells that will proliferate and generate a clinically detectable lesion (5).

Although several of the factors involved in this process are currently known, many issues are still unsolved. For instance, it has not yet been possible to monitor in vivo the specific moment when it occurs 54 ; the microenvironmental factors of the primary tumor that promote such a transition are not known with precision; and the exact moment during tumor evolution in which one cell or a cluster of cells begin to migrate to distant areas, is also unknown. The wide range of possibilities offered by intra- and inter-tumoral heterogeneity 56 stands in the way of suggesting a generalized strategy that could resolve this complication.

It was previously believed that metastasis was only produced in late stages of tumor progression; however, recent studies indicate that EMT and metastasis can occur during the early course of the disease. In pancreatic cancer, for example, cells going through EMT are able to colonize and form metastatic lesions in the liver in the first stages of the disease. 52 , 57 Metastatic cell clusters circulating in peripheral blood (PB) are prone to generate a metastatic site, compared to individual tumor cells. 58 , 59 In this regard, novel strategies, such as the use of micro-RNAs, are being assessed in order to diminish induction of EMT. 60 It must be mentioned, however, that the metastatic process seems to be even more complex, with alternative pathways that do not involve EMT. 61 , 62

A crucial stage in the process of metastasis is the intravasation of tumor cells (alone or in clusters) towards the blood stream and/or lymphatic circulation. 63 These mechanisms are also under intensive research because blocking them could allow the control of spreading of the primary tumor. In PB or lymphatic circulation, tumor cells travel to distant parts for the potential formation of a metastatic lesion. During their journey, these cells must stand the pressure of blood flow and escape interaction with natural killer (NK) cells . 64 To avoid them, tumor cells often cover themselves with thrombocytes and also produce factors such as VEGF, angiopoietin-2, angiopoietin-4, and CCL2 that are involved in the induction of vascular permeability. 54 , 65 Neutrophils also contribute to lung metastasis in the bloodstream by secreting IL-1β and metalloproteases to facilitate extravasation of tumor cells. 64

The next step in the process of metastasis is extravasation, for which tumor cells, alone or in clusters, can use various mechanisms, including a recently described process known as angiopellosis that involves restructuring the endothelial barrier to internalize one or several cells into a tissue. 66 The study of leukocyte extravasation has contributed to a more detailed knowledge of this process, in such a way that some of the proposed strategies to avoid extravasation include the use of integrin inhibitors, molecules that are vital for rolling, adhesion, and extravasation of tumor cells. 67 , 68 Another strategy that has therapeutic potential is the use of antibodies that strengthen vascular integrity to obstruct transendothelial migration of tumor cells and aid in their destruction in PB. 69

Following extravasation, tumor cells can return to an epithelial phenotype, a process known as mesenchymal–epithelial transition and may remain inactive for several years. They do this by competing for specialized niches, like those in the bone marrow, brain, and intestinal mucosa, which provide signals through the Notch and Wnt pathways. 70 Through the action of the Wnt pathway, tumor cells enter a slow state of the cell cycle and induce the expression of molecules that inhibit the cytotoxic function of NK cells. 71 The extravasated tumor cell that is in a quiescent state must comply with 2 traits typical of stem cells: they must have the capacity to self-renew and to generate all of the cells that form the secondary tumor.

There are still several questions regarding the metastatic process. One of the persisting debates at present is if EMT is essential for metastasis or if it plays a more important role in chemoresistance. 61 , 62 It is equally important to know if there is a pattern in each tumor for the production of cells with the capacity to carry out EMT. In order to control metastasis, it is fundamental to know what triggers acquisition of the migratory phenotype and the intrinsic factors determining this transition. Furthermore, it is essential to know if mutations associated with the primary tumor or the variety of epigenetic changes are involved in this process. 55 It is clear that metastatic cells have affinity for certain tissues, depending on the nature of the primary tumor (seed and soil hypothesis). This may be caused by factors such as the location and the direction of the bloodstream or lymphatic fluid, but also by conditioning of premetastatic niches at a distance (due to the large number of soluble factors secreted by the tumor and the recruitment of cells of the immune system to those sites). 72 We have yet to identify and characterize all of the elements that participate in this process. Deciphering them will be of upmost importance from a therapeutic point of view.

Epidemiology of Cancer

Cancer is the second cause of death worldwide; today one of every 6 deaths is due to a type of cancer. According to the International Agency for Research on Cancer (IARC), in 2020 there were approximately 19.3 million new cases of cancer, and 10 million deaths by this disease, 6 while 23.8 million cases and 13.0 million deaths are projected to occur by 2030. 73 In this regard, it is clear the increasing role that environmental factors—including environmental pollutants and processed food—play as cancer inducers and promoters. 74 The types of cancer that produce the greatest numbers of cases and deaths worldwide are indicated in Table 1 . 6

Total Numbers of Cancer Cases and Deaths Worldwide in 2020 by Cancer Type (According to the Global Cancer Observatory, IARC).

Data presented on this table were obtained from Ref. 6.

As shown in Figure 3 , lung, breast, prostate, and colorectal cancer are the most common throughout the world, and they are mostly concentrated in countries of high to very high human development index (HDI). Although breast, prostate, and colorectal cancer have a high incidence, the number of deaths they cause is proportionally low, mostly reflecting the great progress made in their control. However, these data also reveal the types of cancer that require further effort in prevention, precise early detection avoiding overdiagnosis, and efficient treatment. This is the case of liver, lung, esophageal, and pancreatic cancer, where the difference between the number of cases and deaths is smaller ( Figure 3B ). Social and economic transition in several countries has had an impact on reducing the incidence of neoplasms associated with infection and simultaneously produced an increase in the types related to reproductive, dietary, and hormonal factors. 75

Incidence and mortality for some types of cancer in the world. (A) Estimated number of cases and deaths in 2020 for the most frequent cancer types worldwide. (B) Incidence and mortality rates, normalized according to age, for the most frequent cancer types in countries with very high/& high (VH&H; blue) and/low and middle (L&M; red) Human Development Index (HDI). Data include both genders and all ages. Data according to https://gco.iarc.fr/today , as of June 10, 2021.

In the past 3 decades, cancer mortality rates have fallen in high HDI countries, with the exception of pancreatic cancer, and lung cancer in women. Nevertheless, changes in the incidence of cancer do not show the same consistency, possibly due to variables such as the possibility of early detection, exposure to risk factors, or genetic predisposition. 76 , 77 Countries such as Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the United Kingdom have reported a reduction in incidence and mortality in cancer of the stomach, colon, lung, and ovary, as well as an increase in survival. 78 Changes in modifiable risk factors, such as the use of tobacco, have played an important role in prevention. In this respect, it has been estimated that decline in tobacco use can explain between 35% and 45% of the reduction in cancer mortality rates, 79 while the fall in incidence and mortality due to stomach cancer can be attributed partly to the control of Helicobacter pylori infection. 80 Another key factor in the fall of mortality rates in developed countries has been an increase in early detection as a result of screening programs, as in breast and prostate cancer, which have had their mortality rates decreased dramatically in spite of an increase in their incidence. 76

Another important improvement observed in recent decades is the increase in survival rates, particularly in high HDI countries. In the USA, for example, survival rates for patients with prostate cancer at 5 years after initial diagnosis was 28% during 1947–1951; 69% during 1975–1977, and 100% during 2003–2009. Something similar occurred with breast cancer, with a 5-year survival rate of 54% in 1947–1951, 75% in 1975–1977, and 90% in 2003–2009. 81 In the CONCORD 3 version, age-standardize 5-year survival for patients with breast cancer in the USA during 2010–2014 was 90%, and 97% for prostate cancer patients. 82 Importantly, even among high HDI countries, significant differences have been identified in survival rates, being stage of disease at diagnosis, time for access to effective treatment, and comorbidities, the main factors influencing survival in these nations. 78 Unfortunately, survival rates in low HDI countries are significantly lower due to several factors, including lack of information, deficient screening and early detection programs, limited access to treatment, and suboptimal cancer registration. 82 It should be noted that in countries with low to middle HDI, neoplasms with the greatest incidence are those affecting women (breast and cervical cancer), which reflects not only a problem with access to health services, but also a serious inequality issue that involves social, cultural, and even religious obstacles. 83

Up to 42% of incident cases and 47% of deaths by cancer in the USA are due to potentially modifiable risk factors such as use of tobacco, physical activity, diet, and infection. 84 It has been calculated that 2.4 million deaths by cancer, mostly of the lung, can be attributed to tobacco. 73 In 2020, the incidence rate of lung cancer in Western Africa was 2.2, whereas in Polynesia and Eastern Asia was 37.3 and 34.4, respectively. 6 In contrast, the global burden of cancer associated with infection was 15.4%, but in Sub-Saharan Africa it was 30%. 85 Likewise, the incidence of cervical cancer in Eastern Africa was 40.1, in contrast with the USA and Canada that have a rate of 6.2. This makes it clear that one of the challenges we face is the reduction of the risk factors that are potentially modifiable and associated with specific types of cancer.

Improvement of survival rates and its disparities worldwide are also important challenges. Five-year survival for breast cancer—diagnosed during 2010-2014— in the USA, for example, was 90%, whereas in countries like South Africa it was 40%. 82 Childhood leukemia in the USA and several European countries shows a 5-year survival of 90%, while in Latin-American countries it is 50–76%. 86 Interestingly, there are neoplasms, such as pancreatic cancer, for which there has been no significant increase in survival, which remains low (5–15%) both in developed and developing countries. 82

Although data reported on global incidence and mortality gives a general overview on the epidemiology of cancer, it is important to note that there are great differences in coverage of cancer registries worldwide. To date, only 1 out of every 3 countries reports high quality data on the incidence of cancer. 87 For the past 50 years, the IARC has supported population-based cancer registries; however, more than one-third of the countries belonging to the WHO, mainly countries of low and middle income (LMIC), have no data on more than half of the 18 indicators of sustainable development goals. 88 High quality cancer registries only cover 4% of the population in Africa, 8% in Asia, and 7% in Latin America, contrasting with 83% in the USA and Canada, and 33% in Europe. 89 In response to this situation, the Global Initiative for Cancer Registry Development was created in 2012 to generate improved infrastructure to permit greater coverage and better quality registries, especially in countries with low and middle HDI. 88 It is expected that initiatives of this sort in the coming years will allow more and better information to guide strategies for the control of cancer worldwide, especially in developing regions. This will enable survival to be measured over longer periods of time (10, 15, or 20 years), as an effective measure in the control of cancer. The WHO has established as a target for 2025 to reduce deaths by cancer and other non-transmissible diseases by 25% in the population between the ages of 30–69; such an effort requires not only effective prevention measures to reduce incidence, but also more efficient health systems to diminish mortality and increase survival. At the moment, it is an even greater challenge because of the effects of the COVID-19 pandemic which has negatively impacted cancer prevention and health services. 90

Oncologic Treatments

A general perspective.

At the beginning of the 20th century, cancer treatment, specifically treatment of solid tumors, was based fundamentally on surgical resection of tumors, which together with other methods for local control, such as cauterization, had been used since ancient times. 91 At that time, there was an ongoing burst of clinical observations along with interventions sustained on fundamental knowledge about physics, chemistry, and biology. In the final years of the 19 th century and the first half of the 20th, these technological developments gave rise to radiotherapy, hormone therapy, and chemotherapy. 92 - 94 Simultaneously, immunotherapy was also developed, although usually on a smaller scale, in light of the overwhelming progress of chemotherapy and radiotherapy. 95

Thus began the development and expansion of disciplines based on these approaches (surgery, radiotherapy, chemotherapy, hormone therapy, and immunotherapy), with their application evolving ever more rapidly up to their current uses. Today, there is a wide range of therapeutic tools for the care of cancer patients. These include elements that emerged empirically, arising from observations of their effects in various medical fields, as well as drugs that were designed to block processes and pathways that form part of the physiopathology of one or more neoplasms according to knowledge of specific molecular alterations. A classic example of the first sort of tool is mustard gas, originally used as a weapon in war, 96 but when applied for medical purposes, marked the beginning of the use of chemicals in the treatment of malignant neoplasms, that is, chemotherapy. 94 A clear example of the second case is imatinib, designed specifically to selectively inhibit a molecular alteration in chronic myeloid leukemia: the Bcr-Abl oncoprotein. 97

It is on this foundation that today the 5 areas mentioned previously coexist and complement one another. The general framework that motivates this amalgam and guides its development is precision medicine, founded on the interaction of basic and clinical science. In the forecasts for development in each of these fields, surgery is expected to continue to be the fundamental approach for primary tumors in the foreseeable future, as well as when neoplastic disease in the patient is limited, or can be limited by applying systemic or regional elements, before and/or after surgical resection, and it can be reasonably anticipated for the patient to have a significant period free from disease or even to be cured. With regards to technology, intensive exploration of robotic surgery is contemplated. 98

The technological possibilities for radiotherapy have progressed in such a way that it is now possible to radiate neoplastic tissue with an extraordinary level of precision, and therefore avoid damage to healthy tissue. 99 This allows administration of large doses of ionizing radiation in one or a few fractions, what is known as “radiosurgery.” The greatest challenges to the efficacy of this approach are related to radio-resistance in certain neoplasms. Most efforts regarding research in this field are concentrated on understanding the underlying biological mechanisms of the phenomenon and their potential control through radiosensitizers. 100

“Traditional” chemotherapy, based on the use of compounds obtained from plants and other natural products, acting in a non-specific manner on both neoplastic and healthy tissues with a high proliferation rate, continues to prevail. 101 The family of chemotherapeutic drugs currently includes alkylating agents, antimetabolites, anti-topoisomerase agents, and anti-microtubules. Within the pharmacologic perspective, the objective is to attain a high concentration or activity of such molecules in specific tissues while avoiding their accumulation in others, in order to achieve an increase in effectiveness and a reduction in toxicity. This has been possible with the use of viral vectors, for example, that are able to limit their replication in neoplastic tissues, and activate prodrugs of normally nonspecific agents, like cyclophosphamide, exclusively in those specific areas. 102 More broadly, chemotherapy also includes a subgroup of substances, known as molecular targeted therapy, that affect processes in a more direct and specific manner, which will be mentioned later.

There is no doubt that immunotherapy—to be explored next—is one of the therapeutic fields where development has been greatest in recent decades and one that has produced enormous expectation in cancer treatment. 103 Likewise, cell therapy, based on the use of immune cells or stem cells, has come to complement the oncologic therapeutic arsenal. 43 Each and every one of the therapeutic fields that have arisen in oncology to this day continue to prevail and evolve. Interestingly, the foreseeable future for the development of cancer treatment contemplates these approaches in a joint and complementary manner, within the general framework of precision medicine, 104 and sustained by knowledge of the biological mechanisms involved in the appearance and progression of neoplasms. 105 , 106

Immunotherapy

Stimulating the immune system to treat cancer patients has been a historical objective in the field of oncology. Since the early work of William Coley 107 to the achievements reached at the end of the 20 th century, scientific findings and technological developments paved the way to searching for new immunotherapeutic strategies. Recombinant DNA technology allowed the synthesis of cytokines, such as interferon-alpha (IFN-α) and interleukin 2 (IL-2), which were authorized by the US Food and Drug Administration (FDA) for the treatment of hairy cell leukemia in 1986, 108 as well as kidney cancer and metastatic melanoma in 1992 and 1998, respectively. 109

The first therapeutic vaccine against cancer, based on the use of autologous dendritic cells (DCs), was approved by the FDA against prostate cancer in 2010. However, progress in the field of immunotherapy against cancer was stalled in the first decade of the present century, mostly due to failure of several vaccines in clinical trials. In many cases, application of these vaccines was detained by the complexity and cost involved in their production. Nevertheless, with the coming of the concept of immune checkpoint control, and the demonstration of the relevance of molecules such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), and programmed cell death molecule-1 (PD-1), immunotherapy against cancer recovered its global relevance. In 2011, the monoclonal antibody (mAb) ipilimumab, specific to the CTLA-4 molecule, was the first checkpoint inhibitor (CPI) approved for the treatment of advanced melanoma. 110 Later, inhibitory mAbs for PD-1, or for the PD-1 ligand (PD-L1), 111 as well as the production of T cells with chimeric receptors for antigen recognition (CAR-T), 112 which have been approved to treat various types of cancer, including melanoma, non-small cell lung cancer (NSCLC), head and neck cancer, bladder cancer, renal cell carcinoma (RCC), and hepatocellular carcinoma, among others, have changed the paradigm of cancer treatment.

In spite of the current use of anti-CTLA-4 and anti-PD-L1 mAbs, only a subgroup of patients has responded favorably to these CPIs, and the number of patients achieving clinical benefit is still small. It has been estimated that more than 70% of patients with solid tumors do not respond to CPI immunotherapy because either they show primary resistance, or after responding favorably, develop resistance to treatment. 113 In this regard, it is important to mention that in recent years very important steps have been taken to identify the intrinsic and extrinsic mechanisms that mediate resistance to CPI immunotherapy. 114 Intrinsic mechanisms include changes in the antitumor immune response pathways, such as faulty processing and presentation of antigens by APCs, activation of T cells for tumor cell destruction, and changes in tumor cells that lead to an immunosuppressive TME. Extrinsic factors include the presence of immunosuppressive cells in the local TME, such as regulatory T cells, myeloid-derived suppressor cells (MDSC), mesenchymal stem/stromal cells (MSCs), and type 2 macrophages (M2), in addition to immunosuppressive cytokines.

On the other hand, classification of solid tumors as “hot,” “cold,” or “excluded,” depending on T cell infiltrates and the contact of such infiltrates with tumor cells, as well as those that present high tumor mutation burden (TMB), have redirected immunotherapy towards 3 main strategies 115 ( Table 2 ): (1) Making T-cell antitumor response more effective, using checkpoint inhibitors complementary to anti-CTLA-4 and anti-PD-L1, such as LAG3, Tim-3, and TIGT, as well as using CAR-T cells against tumor antigens. (2) Activating tumor-associated myeloid cells including monocytes, granulocytes, macrophages, and DC lineages, found at several frequencies within human solid tumors. (3) Regulating the biochemical pathways in TME that produce high concentrations of immunosuppressive molecules, such as kynurenine, a product of tryptophan metabolism, through the activity of indoleamine 2,3 dioxygenase; or adenosine, a product of ATP hydrolysis by the activity of the enzyme 5’nucleotidase (CD73). 116

Current Strategies to Stimulate the Immune Response for Antitumor Immunotherapy.

Abbreviations: TME, tumor microenvironment; IL, interleukin; TNF, Tumor Necrosis Factor; TNFR, TNF-receptor; CD137, receptor–co-stimulator of the TNFR family; OX40, member number 4 of the TNFR superfamily; CD27/CD70, member of the TNFR superfamily; CD40/CD40L, antigen-presenting cells (APC) co-stimulator and its ligand; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; STING, IFN genes-stimulator; RIG-I, retinoic acid inducible gene-I; MDA5, melanoma differentiation-associated protein 5; CDN, cyclic dinucleotide; ATP, adenosine triphosphate; HMGB1, high mobility group B1 protein; TLR, Toll-like receptor; HVEM, Herpes virus entry mediator; GITR, glucocorticoid-induced TNFR family-related gene; CTLA4, cytotoxic T lymphocyte antigen 4; PD-L1, programmed death ligand-1; TIGIT, T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibition motives; CSF1/CSF1R, colony-stimulating factor-1 and its receptor; CCR2, Type 2 chemokine receptor; PI3Kγ, Phosphoinositide 3-Kinase γ; CXCL/CCL, chemokine ligands; LFA1, lymphocyte function-associated antigen 1; ICAM1, intercellular adhesion molecule 1; VEGF, vascular endothelial growth factor; IDO, indolamine 2,3-dioxigenase; TGF, transforming growth factor; LAG-3, lymphocyte-activation gene 3 protein; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; CD73, 5´nucleotidase; ARs, adenosine receptors; Selectins, cell adhesion molecules; CAR-T, chimeric antigen receptor T cell; TCR-T, T-cell receptor engineered T cell.

Apart from the problems associated with its efficacy (only a small group of patients respond to it), immunotherapy faces several challenges related to its safety. In other words, immunotherapy can induce adverse events in patients, such as autoimmunity, where healthy tissues are attacked, or cytokine release syndrome and vascular leak syndrome, as observed with the use of IL-2, both of which lead to serious hypotension, fever, renal failure, and other adverse events that are potentially lethal. The main challenges to be faced by immunotherapy in the future will require the combined efforts of basic and clinical scientists, with the objective of accelerating the understanding of the complex interactions between cancer and the immune system, and improve treatment options for patients. Better comprehension of immune phenotypes in tumors, beyond the state of PD-L1 and TME, will be relevant to increase immunotherapy efficacy. In this context, the identification of precise tumor antigenicity biomarkers by means of new technologies, such as complete genome sequencing, single cell sequencing, and epigenetic analysis to identify sites or subclones typical in drug resistance, as well as activation, traffic and infiltration of effector cells of the immune response, and regulation of TME mechanisms, may help define patient populations that are good candidates for specific therapies and therapeutic combinations. 117 , 118 Likewise, the use of agents that can induce specific activation and modulation of the response of T cells in tumor tissue, will help improve efficacy and safety profiles that can lead to better clinical results.

Molecular Targeted Therapy

For over 30 years, and based on the progress in our knowledge of tumor biology and its mechanisms, there has been a search for therapeutic alternatives that would allow spread and growth of tumors to be slowed down by blocking specific molecules. This approach is known as molecular targeted therapy. 119 Among the elements generally used as molecular targets there are transcription factors, cytokines, membrane receptors, molecules involved in a variety of signaling pathways, apoptosis modulators, promoters of angiogenesis, and cell cycle regulators. 120

Imatinib, a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia, became the first targeted therapy in the final years of the 1990s. 97 From then on, new drugs have been developed by design, and today more than 60 targeted therapies have been approved by the FDA for the treatment of a variety of cancers ( Table 3 ). 121 This has had a significant impact on progression-free survival and global survival in neoplasms such as non-small cell lung cancer, breast cancer, renal cancer, and melanoma.

FDA Approved Molecular Targeted Therapies for the Treatment of Solid Tumors.

Abbreviations: mAb, monoclonal antibody; ALK, anaplastic lymphoma kinase; CDK, cyclin-dependent kinase; CTLA-4, cytotoxic lymphocyte antigen-4; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; GIST, gastrointestinal stroma tumor; mTOR, target of rapamycine in mammal cells; NSCLC, non-small cell lung carcinoma; PARP, poli (ADP-ribose) polimerase; PD-1, programmed death protein-1; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed death ligand-1; ER, estrogen receptor; PR, progesterone receptor; TKR, tyrosine kinase receptors; SERM, selective estrogen receptor modulator; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor. Modified from Ref. [ 127 ].

Most drugs classified as targeted therapies form part of 2 large groups: small molecules and mAbs. The former are defined as compounds of low molecular weight (<900 Daltons) that act upon entering the cell. 120 Targets of these compounds are cell cycle regulatory proteins, proapoptotic proteins, or DNA repair proteins. These drugs are indicated based on histological diagnosis, as well as molecular tests. In this group there are multi-kinase inhibitors (RTKs) and tyrosine kinase inhibitors (TKIs), like sunitinib, sorafenib, and imatinib; cyclin-dependent kinase (CDK) inhibitors, such as palbociclib, ribociclib and abemaciclib; poli (ADP-ribose) polimerase inhibitors (PARPs), like olaparib and talazoparib; and selective small-molecule inhibitors, like ALK and ROS1. 122

As for mAbs, they are protein molecules that act on membrane receptors or extracellular proteins by interrupting the interaction between ligands and receptors, in such a way that they reduce cell replication and induce cytostasis. Among the most widely used mAbs in oncology we have: trastuzumab, a drug directed against the receptor for human epidermal growth factor-2 (HER2), which is overexpressed in a subgroup of patients with breast and gastric cancer; and bevacizumab, that blocks vascular endothelial growth factor and is used in patients with colorectal cancer, cervical cancer, and ovarian cancer. Other mAbs approved by the FDA include pembolizumab, atezolizumab, nivolumab, avelumab, ipilimumab, durvalumab, and cemiplimab. These drugs require expression of response biomarkers, such as PD-1 and PD-L1, and must also have several resistance biomarkers, such as the expression of EGFR, the loss of PTEN, and alterations in beta-catenin. 123

Because cancer is such a diverse disease, it is fundamental to have precise diagnostic methods that allow us to identify the most adequate therapy. Currently, basic immunohistochemistry is complemented with neoplastic molecular profiles to determine a more accurate diagnosis, and it is probable that in the near future cancer treatments will be based exclusively on molecular profiles. In this regard, it is worth mentioning that the use of targeted therapy depends on the existence of specific biomarkers that indicate if the patient will be susceptible to the effects of the drug or not. Thus, the importance of underlining that not all patients are susceptible to receive targeted therapy. In certain neoplasms, therapeutic targets are expressed in less than 5% of the diagnosed population, hindering a more extended use of certain drugs.

The identification of biomarkers and the use of new generation sequencing on tumor cells has shown predictive and prognostic relevance. Likewise, mutation analysis has allowed monitoring of tumor clone evolution, providing information on changes in canonic gene sequences, such as TP53, GATA3, PIK3CA, AKT1, and ERBB2; infrequent somatic mutations developed after primary treatments, like SWI-SNF and JAK2-STAT3; or acquired drug resistance mutations such as ESR1. 124 The study of mutations is vital; in fact, many of them already have specific therapeutic indications, which have helped select adequate treatments. 125

There is no doubt that molecular targeted therapy is one of the main pillars of precision medicine. However, it faces significant problems that often hinder obtaining better results. Among these, there is intratumor heterogeneity and differences between the primary tumor and metastatic sites, as well as intrinsic and acquired resistance to these therapies, the mechanisms of which include the presence of heterogeneous subclones, DNA hypermethylation, histone acetylation, and interruption of mRNA degradation and translation processes. 126 Nonetheless, beyond the obstacles facing molecular targeted therapy from a biological and methodological point of view, in the real world, access to genomic testing and specific drugs continues to be an enormous limitation, in such a way that strategies must be designed in the future for precision medicine to be possible on a global scale.

Cell Therapy

Another improvement in cancer treatment is the use of cell therapy, that is, the use of specific cells as therapeutic agents. This clinical procedure has 2 modalities: the first consists of replacing and regenerating functional cells in a specific tissue by means of stem/progenitor cells of a certain kind, 43 while the second uses immune cells as effectors to eliminate malignant cells. 127

Regarding the first type, we must emphasize the development of cell therapy based on hematopoietic stem and progenitor cells. 128 For over 50 years, hematopoietic cell transplants have been used to treat a variety of hematologic neoplasms (different forms of leukemia and lymphoma). Today, it is one of the most successful examples of cell therapy, including innovative modalities, such as haploidentical transplants, 129 as well as application of stem cells expanded ex vivo . 130 There are also therapies that have used immature cells that form part of the TME, such as MSCs. The replication potential and cytokine secretion capacity of these cells make them an excellent option for this type of treatment. 131 Neural stem cells can also be manipulated to produce and secrete apoptotic factors, and when these cells are incorporated into primary neural tumors, they cause a certain degree of regression. They can even be transfected with genes that encode for oncolytic enzymes capable of inducing regression of glioblastomas. 132

With respect to cell therapy using immune cells, several research groups have manipulated cells associated with tumors to make them effector cells and thus improve the efficacy and specificity of the antitumor treatment. PB leckocytes cultured in the presence of IL-2 to obtain activated lymphocytes, in combination with IL-2 administration, have been used in antitumor clinical protocols. Similarly, infiltrating lymphocytes from tumors with antitumor activity have been used and can be expanded ex vivo with IL-2. These lymphocyte populations have been used in immunomodulatory therapies in melanoma, and pancreatic and kidney tumors, producing a favorable response in treated patients. 133 NK cells and macrophages have also been used in immunotherapy, although with limited results. 134 , 135

One of the cell therapies with better projection today is the use of CAR-T cells. This strategy combines 2 forms of advanced therapy: cell therapy and gene therapy. It involves the extraction of T cells from the cancer patient, which are genetically modified in vitro to express cell surface receptors that will recognize antigens on the surface of tumor cells. The modified T cells are then reintroduced in the patient to aid in an exacerbated immune response that leads to eradication of the tumor cells ( Figure 4 ). Therapy with CAR-T cells has been used successfully in the treatment of some types of leukemia, lymphoma, and myeloma, producing complete responses in patients. 136

CAR-T cell therapy. (A) T lymphocytes obtained from cancer patients are genetically manipulated to produce CAR-T cells that recognize tumor cells in a very specific manner. (B) Interaction between CAR molecule and tumor antigen. CAR molecule is a receptor that results from the fusion between single-chain variable fragments (scFv) from a monoclonal antibody and one or more intracellular signaling domains from the T-cell receptor. CD3ζ, CD28 and 4-1BB correspond to signaling domains on the CAR molecule.

Undoubtedly, CAR-T cell therapy has been truly efficient in the treatment of various types of neoplasms. However, this therapeutic strategy can also have serious side effects, such as release of cytokines into the bloodstream, which can cause different symptoms, from high fever to multiorgan failure, and even neurotoxicity, leading to cerebral edema in many cases. 137 Adequate control of these side effects is an important medical challenge. Several research groups are trying to improve CAR-T cell therapy through various approaches, including production of CAR-T cells directed against a wider variety of tumor cell-specific antigens that are able to attack different types of tumors, and the identification of more efficient types of T lymphocytes. Furthermore, producing CAR-T cells from a single donor that may be used in the treatment of several patients would reduce the cost of this sort of personalized cell therapy. 136

Achieving wider use of cell therapy in oncologic diseases is an important challenge that requires solving various issues. 138 One is intratumor cell heterogeneity, including malignant subclones and the various components of the TME, which results in a wide profile of membrane protein expression that complicates finding an ideal tumor antigen that allows specific identification (and elimination) of malignant cells. Likewise, structural organization of the TME challenges the use of cell therapy, as administration of cell vehicles capable of recognizing malignant cells might not be able to infiltrate the tumor. This results from low expression of chemokines in tumors and the presence of a dense fibrotic matrix that compacts the inner tumor mass and avoids antitumor cells from infiltrating and finding malignant target cells.

Further Challenges in the 21st Century

Beyond the challenges regarding oncologic biomedical research, the 21 st century is facing important issues that must be solved as soon as possible if we truly wish to gain significant ground in our fight against cancer. Three of the most important have to do with prevention, early diagnosis, and access to oncologic medication and treatment.

Prevention and Early Diagnosis

Prevention is the most cost-effective strategy in the long term, both in low and high HDI nations. Data from countries like the USA indicate that between 40-50% of all types of cancer are preventable through potentially modifiable factors (primary prevention), such as use of tobacco and alcohol, diet, physical activity, exposure to ionizing radiation, as well as prevention of infection through access to vaccination, and by reducing exposure to environmental pollutants, such as pesticides, diesel exhaust particles, solvents, etc. 74 , 84 Screening, on the other hand, has shown great effectiveness as secondary prevention. Once population-based screening programs are implemented, there is generally an initial increase in incidence; however, in the long term, a significant reduction occurs not only in incidence rates, but also in mortality rates due to detection of early lesions and timely and adequate treatment.

A good example is colon cancer. There are several options for colon cancer screening, such as detection of fecal occult blood, fecal immunohistochemistry, flexible sigmoidoscopy, and colonoscopy, 139 , 140 which identify precursor lesions (polyp adenomas) and allow their removal. Such screening has allowed us to observe 3 patterns of incidence and mortality for colon cancer between the years 2000 and 2010: on one hand, an increase in incidence and mortality in countries with low to middle HDI, mainly countries in Asia, South America, and Eastern Europe; on the other hand, an increase in incidence and a fall in mortality in countries with very high HDI, such as Canada, the United Kingdom, Denmark, and Singapore; and finally a fall in incidence and mortality in countries like the USA, Japan, and France. The situation in South America and Asia seems to reflect limitations in medical infrastructure and a lack of access to early detection, 141 while the patterns observed in developed countries reveal the success, even if it may be partial, of that which can be achieved by well-structured prevention programs.

Another example of success, but also of strong contrast, is cervical cancer. The discovery of the human papilloma virus (HPV) as the causal agent of cervical cancer brought about the development of vaccines and tests to detect oncogenic genotypes, which modified screening recommendations and guidelines, and allowed several developed countries to include the HPV vaccine in their national vaccination programs. Nevertheless, the outlook is quite different in other areas of the world. Eighty percent of the deaths by cervical cancer reported in 2018 occurred in low-income nations. This reveals the urgency of guaranteeing access to primary and secondary prevention (vaccination and screening, respectively) in these countries, or else it will continue to be a serious public health problem in spite of its preventability.

Screening programs for other neoplasms, such as breast, prostate, lung, and thyroid cancer have shown outlooks that differ from those just described, because, among other reasons, these neoplasms are highly diverse both biologically and clinically. Another relevant issue is the overdiagnosis of these neoplasms, that is, the diagnosis of disease that would not cause symptoms or death in the patient. 142 It has been calculated that 25% of breast cancer (determined by mammogram), 50–60% of prostate cancer (determined by PSA), and 13–25% of lung cancer (determined by CT) are overdiagnosed. 142 Thus, it is necessary to improve the sensitivity and specificity of screening tests. In this respect, knowledge provided by the biology of cancer and “omic” sciences offers a great opportunity to improve screening and prevention strategies. All of the above shows that prevention and early diagnosis are the foundations in the fight against cancer, and it is essential to continue to implement broader screening programs and better detection methods.

Global Equity in Oncologic Treatment

Progress in cancer treatment has considerably increased the number of cancer survivors. Nevertheless, this tendency is evident only in countries with a very solid economy. Indeed, during the past 30 years, cancer mortality rates have increased 30% worldwide. 143 Global studies indicate that close to 70% of cancer deaths in the world occur in nations of low to middle income. But even in high-income countries, there are sectors of society that are more vulnerable and have less access to cancer treatments. 144 Cancer continues to be a disease of great social inequality.

In Europe, the differences in access to cancer treatment are highly marked. These treatments are more accessible in Western Europe than in its Eastern counterpart. 145 Furthermore, highly noticeable differences between high-income countries have been detected in the cost of cancer drugs. 146 It is interesting to note that in many of these cases, treatment is too costly and the clinical benefit only marginal. Thus, the importance of these problems being approached by competent national, regional, and global authorities, because if these new drugs and therapeutic programs are not accessible to the majority, progress in biomedical, clinical and epidemiological research will have a limited impact in our fight against cancer. We must not forget that health is a universal right, from which low HDI countries must not be excluded, nor vulnerable populations in nations with high HDI. The participation of a well-informed society will also be fundamental to achieve a global impact, as today we must fight not only against the disease, but also against movements and ideas (such as the anti-vaccine movement and the so-called miracle therapies) that can block the medical battle against cancer.

Final Comments

From the second half of the 20th century to the present day, progress in our knowledge about the origin and development of cancer has been extraordinary. We now understand cancer in detail in genomic, molecular, cellular, and physiological terms, and this knowledge has had a significant impact in the clinic. There is no doubt that a patient who is diagnosed today with a type of cancer has a better prospect than a patient diagnosed 20 or 50 years ago. However, we are still far from winning the war against cancer. The challenges are still numerous. For this reason, oncologic biomedical research must be a worldwide priority. Likewise, one of the fundamental challenges for the coming decades must be to reduce unequal access to health services in areas of low- to middle income, and in populations that are especially vulnerable, as well as continue improving prevention programs, including public health programs to reduce exposure to environmental chemicals and improve diet and physical activity in the general population. 74 , 84 Fostering research and incorporation of new technological resources, particularly in less privileged nations, will play a key role in our global fight against cancer.

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Hector Mayani https://orcid.org/0000-0002-2483-3782

Primary site

Cancer treatment before and after physician-pharmacy integration.

Importance   Integration of pharmacies with physician practices, also known as medically integrated dispensing, is increasing in oncology. However, little is known about how this integration affects drug use, expenditures, medication adherence, or time to treatment initiation.

Objective   To examine the association of physician-pharmacy integration with oral oncology drug expenditures, use, and patient-centered measures.

Design, Setting, and Participants   This cohort study used claims data from a large commercial insurer in the US to analyze changes in outcome measures among patients treated by pharmacy-integrating vs nonintegrating community oncologists in 14 states between January 1, 2011, and December 31, 2019. Commercially insured patients were aged 18 to 64 years with 1 of the following advanced-stage diagnoses: breast cancer, colorectal cancer, kidney cancer, lung cancer, melanoma, or prostate cancer. Data analysis was conducted from May 2023 to March 2024.

Exposure   Treatment by a pharmacy-integrating oncologist, ascertained by the presence of an on-site pharmacy or nonpharmacy dispensing site.

Main Outcomes and Measures   Oral, intravenous (IV), total, and out-of-pocket drug expenditures for a 6-month episode of care; share of patients prescribed oral drugs; days’ supply of oral drugs; medication adherence measured by proportion of days covered; and time to treatment initiation. The association between an oncologist’s pharmacy integration and each outcome of interest was estimated using the difference-in-differences estimator.

Results   Between 2012 and 2019, 3159 oncologists (745 females [27.1%], 2002 males [72.9%]) treated 23 968 patients (66.4% female; 53.4% aged 55-64 years). Of the 3159 oncologists, 578 (18.3%) worked in practices that integrated with pharmacies (with a low rate in 2011 of 0% and a high rate in 2019 of 31.5%). In the full sample (including all cancer sites), after physician-pharmacy integration, no significant changes were found in oral drug expenditures, IV drug expenditures, or total drug expenditures. There was, however, an increase in days’ supply of oral drugs (5.96 days; 95% CI, 0.64-11.28 days;  P  = .001). There were no significant changes in out-of-pocket expenditures, medication adherence, or time to treatment initiation of oral drugs. In the breast cancer sample, there was an increase in oral drug expenditures ($244; 95% CI, $41-$446;  P  = .02) and a decrease in IV drug expenditures (–$4187; 95% CI, –$8293 to –$80;  P  = .05).

Conclusions and Relevance   Results of this cohort study indicated that the integration of oncology practices with pharmacies was not associated with significant changes in expenditures or clear patient-centered benefits.

The full study can be viewed at JAMA Network Open .

Kanter GP, Ozluk P, Chi W, et al. Cancer Treatment Before and After Physician-Pharmacy Integration.  JAMA Netw Open.  2024;7(5):e2412998. doi:10.1001/jamanetworkopen.2024.12998

Related Work

Study: Integration of Pharmacies with Physician Practices Has Little Impact on Cancer Drug Expenditures